st is in DialUnits
? b 410
21ju108 15:14:52 User208760 Session D2961.1
  $0.55  0.152 DialUnits File1
$0.55 Estimated cost File1
$0.55 Estimated cost this search
$0.55 Estimated total session cost  0.152 DialUnits

File 410: Dialog Comm.-of-Interest Newsletters 2008 /Mar
(c) 2008 Dialog

Set  Items  Description
---  -----  ---------------

? set hi ;set hi
HILIGHT set on as ''
HILIGHT set on as ''
? begin 5,73,155,399
21ju108 15:14:57 User208760 Session D2961.2
         $0.00  0.117 DialUnits File410
$0.00 Estimated cost File410
$0.02 TELNET
$0.02 Estimated cost this search
$0.57 Estimated total session cost  0.269 DialUnits

SYSTEM:OS - DIALOG OneSearch
File  5:Biosis Previews(R) 1926-2008/Jul W2
(c) 2008 The Thomson Corporation
File  73:EMBASE 1974-2008/Jul 18
(c) 2008 Elsevier B.V.
File 155:MEDLINE(R) 1950-2008/Jul 17
(c) format only 2008 Dialog
File 399:CA SEARCH(R) 1967-2008/UD=14904
(c) 2008 American Chemical Society

*File 399: Use is subject to the terms of your user/customer agreement. IFCR/8 classification codes now searchable as IC=. See HELP NEWSIPCR.

Set  Items  Description
---  -----  ---------------

? s (cd40)(10n)(agonist?) and (cd20 or rituxan or rituximab)
   34908  CD40
   589238 AGONIST?
       698  CD40(10N)AGONIST?
       21687  CD20
       1876  RITUXAN
       20705  RITUXIMAB
S1    15 (CD40)(10N)(AGONIST?) AND (CD20 OR RITUXAN OR RITUXIMAB)
? rd s1
  S2    9  RD S1 (unique items)
? t s2/3/all

2/3/1  (Item 1 from file: 5)
DIALOG(R)File  5:Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

18839939  BIOSIS NO.: 200600185334
Humanized anti CD-40 antibody SGN-40 effectively induces cytotoxicity against chronic lymphocytic leukemia (CLL) cells through antibody mediated cytotoxicity and demonstrates modest biologic evidence of CD40 activation
AUTHOR: Gowda Aruna C (Reprint); Zhao Xiaobin B; Cheney Carolyn; Mehter Najma; Lozanski Gerard; Lin Thomas S; Guster Sara; Drachman J G;
2/3/2  (Item 2 from file: 5)
DIALOG(R)File  5:Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

18618720  BIOSIS NO.: 200510313220
Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40
AUTHOR: Law Che-Leung (Reprint); Gordon Kristine A; Collier John; Klussman Kerry; McEarchern Julie A; Cerveny Charles G; Mixan Bruce J; Lee Wyne P; Lin Zhonghua; Valdez Patricia; Wahl Alan F; Grewal Iqbal S
AUTHOR ADDRESS: Seattle Genet Inc, 21823 30th Dr SE, Bothell, WA 98021 USA
**USA
AUTHOR E-MAIL ADDRESS: claw@seagen.com
ISSN: 0008-5472
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

2/3/3  (Item 3 from file: 5)
DIALOG(R)File  5:Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

18576751  BIOSIS NO.: 200510271251
A fully human anti-CD40 antagonistic antibody, CHIR-12.12, inhibit the proliferation of human B cell non-Hodgkin's lymphoma
AUTHOR: Weng Wen-Kai (Reprint); Tong Xia; Lugman Mohammad; Levy Ronald
AUTHOR ADDRESS: Stanford Univ, Sch Med, Stanford, CA 94305 USA**USA
CONFERENCE/MEETING: 46th Annual Meeting of the American-Society-of-Hematology San Diego, CA, USA December 04 -07, 2004;
20041204
SPONSOR: Amer Soc Hematol
ISSN: 0006-4971
DOCUMENT TYPE: Meeting; Meeting Poster
RECORD TYPE: Abstract
LANGUAGE: English

2/3/4  (Item 4 from file: 5)
DIALOG(R)File  5:Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

18234887  BIOSIS NO.: 200500141952
Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival
AUTHOR: Adams Andrew B; Shirasugi Nozomu; Jones Thomas R; Durham Megan M;
Human anti-CD40 antagonistic antibodies inhibit the proliferation of human B cell non-Hodgkin's lymphoma

AUTHOR: Weng Wen-Kai (Reprint); Wang Changyu; Chu Keting; Levy Ronald (Reprint)

AUTHOR ADDRESS: Medicine/Oncology, Stanford University, Stanford, CA, USA


CONFERENCE/MEETING: 43rd Annual Meeting of the American Society of Hematology, Part 1 Orlando, Florida, USA December 07-11, 2001; 20011207

SPONSOR: American Society of Hematology

ISSN: 0006-4971

DOCUMENT TYPE: Meeting; Meeting Abstract

RECORD TYPE: Abstract

LANGUAGE: English

Agonistic and antagonistic properties of CD40 mAb G28-5 are dependent on binding valency

AUTHOR: Ledbetter Jeffrey A (Reprint); Grosnaire Laura S; Hollenbaugh Diane ; Aruffo Alejandro; Nadler Steven G

AUTHOR ADDRESS: Bristol-Myers Squibb, Pharm. Res. Inst., 3005 First Ave., Seattle, WA 98121, USA**USA


ISSN: 0092-6213

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

Cancer: Novel therapeutic strategies that exploit the TNF-related...
apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway
Cretney E.; Takeda K.; Smyth M.J.
Cancer Immunology Program, Trescowthick Research Laboratories, Peter MacCallum Cancer Centre, East Melbourne, Vic. 3002, Australia
AUTHOR EMAIL: mark.smith@petermac.org
CORRESP. AUTHOR/AFFIL: Smyth M.J.: Cancer Immunology Program, Trescowthick Research Laboratories, Peter MacCallum Cancer Centre, East Melbourne, Vic. 3002, Australia
CORRESP. AUTHOR EMAIL: mark.smith@petermac.org

CODEN: IJBBF ISSN: 1357-2725
PUBLISHER ITEM IDENTIFIER: S1357272506002792
DOI: 10.1016/j.biocel.2006.10.005
DOCUMENT TYPE: Journal; Short Survey RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 44

2/3/8 (Item 2 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0077090181 EMBASE No: 1997383451
Agonistic activity of a CD40-specific single-chain Fv constructed from the variable regions of mAb G28-5
Bristol-Myers Squibb P., 3005 First Avenue, Seattle, WA 98121, United States
CORRESP. AUTHOR/AFFIL: Nadler S.G.: BMS Pharmaceut. Research Institute, 3005 First Avenue, Seattle, WA 98121, United States

Critical Reviews in Immunology (CRIT. REV. IMMUNOL.) (United States) December 1, 1997, 17/5-6 (427-435)
CODEN: CCRID ISSN: 1040-8401
DOCUMENT TYPE: Journal; Conference Paper RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 26

2/3/9 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2008 American Chemical Society. All rts. reserv.

143241996 CA: 143(14)241996f PATENT
Methods using a toll-like receptor-2 (TLR2) agonist for treating immunopathological disorders
INVENTOR(AUTHOR): Raz, Eyal; Redecke, Vanessa Doreen; Horner, Anthony A.
LOCATION: USA
ASSIGNEE: The Regents of the University of California
PATENT: PCT International; WO 200579419 A2 DATE: 20050901
PAGES: 50 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: A61K-000/0A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS;
Humanized anti CD-40 antibody SGN-40 effectively induces cytotoxicity against chronic lymphocytic leukemia (CLL) cells through antibody-mediated cytotoxicity and demonstrates modest biologic evidence of CD40 activation

AUTHOR: Gowda Aruna C (Reprint); Zhao Xiaobin B; Cheney Carolyn; Mehter Najma; Lozanski Gerard; Lin Thomas S; Guster Sara; Drachman J G; Muthusamy Natarajan; Byrd John C

AUTHOR ADDRESS: Ohio State Univ, Columbus, OH 43210 USA**USA


SPONSOR: Amer Soc Hematol

ISSN: 0006-4971

DOCUMENT TYPE: Meeting; Meeting Poster

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: The CD40 antigen is involved in cell survival and differentiation of B-cells and is uniformly expressed on chronic lymphocytic leukemia (CLL) cells. The CD40/CD40L interaction stimulates B-cells, dendritic cells and monocytes to proliferate, differentiate, up regulate co-stimulatory molecules and increase antigen presentation. While activation of CD40 can protect CLL cells against early fludarabine-induced apoptosis, these cells become sensitive to delayed death by extrinsic pathway apoptosis. (Blood, 105: 3193-8, 2005). SGN-40 is a humanized anti-CD40 antibody entering clinical trials and has been reported to have weak agonistic properties following CD40 ligation. To pursue rational clinical development of SGN-40, we studied the effects of this antibody in fresh, non-cryopreserved primary CLL cells. These studies included classic antibody mediated killing mechanisms and evidence of both CLL cell activation and protection against early fludarabine-mediated apoptosis. CLL cells treated with SGN-40 (10 mcg/ml) for 2 hours (hrs) in the presence of human serum promoted no complement mediated cytotoxicity (CDC) in 8 pts tested. Direct SGN-40 induced apoptosis of human CLL cells with or without anti-Fc IgG cross-linking at 24, 48 and 72 hrs was not increased over that observed with the isotype control antibody trastuzumab in 8 pts studied. In contrast, SGN-40 induced antibody dependent cellular cytotoxicity (ADCC) against CLL cells an average of 12% (+/- 11.39 SD, range 2-32%) killing at 4 hrs (effector to target cell ratio 25: 1) in 6 pts tested. The SGN-40 induced ADCC against CLL cells were similar to that observed with alemtuzumab (average 19%, SD 6.9, range 10-30%) or **rituximab*** (average 18%, SD 12.48, range 8-42.5%). SGN-40 also mediated death in Raji and 697 lymphoblastic lymphoma cell lines via ADCC. Similar to reports by others with CD40 ligand, SGN-40 mediated activation was noted with modest up-regulation of CD80 and HLA-DR at 48hrs. When administered
prior to fludarabine, SGN-40 also protected against death in 5 consecutive samples, although this was less than observed with CD40 ligand transfected HeLa cells, consistent with incomplete CD40 activation. Concurrent administration of SGN-40 and fludarabine did not protect from drug-mediated apoptosis. In conclusion, these findings suggest that SGN-40 has dual property of mediating cytotoxic effect by ADCC and partial CD40 activation. Development of SGN-40 as a therapeutic agent in CLL is justified and future studies by our group are focusing on enhancing SGN-40 mediated ADCC against CLL cells and potentially designing combination studies with SGN-40 to exploit this agent's ability to engage the CD40/CD40L network.

2/7/2    (Item 2 from file: 5)
DIALOG(R)File    5:Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

18618720    BIOSIS NO.: 200510313200
Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40
AUTHOR: Law Che-Leung (Reprint); Gordon Kristine A; Collier John; Klussman Kerry; McEarchern Julie A; Cerveny Charles G; Mixan Bruce J; Lee Wyne P; Lin Zhonghau; Valdez Patricia; Wahl Alan F; Grewal Iqbal S
AUTHOR ADDRESS: Seattle Genet Inc, 21823 30th Dr SE, Bothell, WA 98021 USA **USA
AUTHOR E-MAIL ADDRESS: claw@seagen.com
ISSN: 0008-5472
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: SGN-40 is a humanized IgG1 anti-human CD40 that is currently in a phase I clinical trial for the treatment of multiple myeloma. As surface CD40 expression on B-lineage cells is maintained from pro-B cells to plasma cells, SGN-40 may be applicable to treatment of other B-cell neoplasias, including non-Hodgkin's lymphoma. In this study, we examined potential in vitro and in vivo anti-B-lineage lymphoma activity of SGN-40. Recombinant SGN-40 was expressed and purified from Chinese hamster ovary cells and characterized based on binding affinity, specificity, and normal B-cell stimulation. The ability of SGN-40 to target neoplastic B cells was examined in vitro by proliferation inhibition, cytotoxicity, and antibody-dependent cell cytotoxicity assays and in vivo by human lymphoma xenograft models. Recombinant SGN-40 showed high affinity, K-d of similar to 1 nmol/L, and specific binding to ***CD40*** . Whereas SGN-40 was a weak ***agonist*** in stimulating normal B-cell proliferation in the absence of IL-4 and CD40L, it delivered potent proliferation inhibitory and apoptotic signals to, and mediated antibody-dependent cytotoxicity against, a panel of high-grade B-lymphoma lines. These in vitro antilymphoma effects were extended to disseminated and s.c. xenograft CD40 tumor models. In these xenograft models, the antitumor activity of SGN-40 was comparable with that of ***rituximab*** . The preclinical in vitro and in vivo antilymphoma activity of SGN40 observed in this study provides a rationale for the clinical testing of SGN-40 in the treatment of CD40(+) B-lineage lymphomas.
A fully human anti-CD40 antagonistic antibody, CHIR-12.12, inhibit the proliferation of human B cell non-Hodgkin's lymphoma

AUTHOR: Weng Wen-Kai (Reprint); Tong Xia; Luqman Mohammad; Levy Ronald

AUTHOR ADDRESS: Stanford Univ, Sch Med, Stanford, CA 94305 USA**USA


CONFERENCE/MEETING: 46th Annual Meeting of the American-Society-of-Hematology San Diego, CA, USA December 04 -07, 2004; 20041204

SPONSOR: Amer Soc Hematol

ISSN: 0006-4971

DOCUMENT TYPE: Meeting; Meeting Poster

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: Immunotherapy using anti-tumor antibodies has become a feasible alternative for treating patients with lymphoma. These anti-tumor antibodies may target a specific receptor to disrupt proliferative signaling or mediate their anti-tumoreffect by antibody-dependent cellular cytotoxicity (ADCC) or complement-mediated killing. The CD40 antigen is a good target for such anti-tumor antibodies for several reasons: CD40 is expressed on the vast majority of the non-Hodgkin's B cell lymphomas and it has been proposed that the CD40/CD40L interaction provides a critical survival or proliferative signal for B cell lymphoma, especially the low-grade follicular lymphoma. In addition, B lymphoma cell lines become less sensitive to chemotherapy-induced apoptosis after CD40 cross-linking in an in vivo study. Therefore, an anti-CD40 antagonist that disrupts the CD40/CD40L interaction and mediates effector mechanism could have a therapeutic advantage. In this report, we describe a fully human anti-CD40 antagonistic IgG1 monoclonal antibody, CHIR-12.12 that was generated from mice with a human immunoglobulin gene loci (XenoMouse (R) mice, Abgenix Inc.). We first compared the antigen expression level of CD40 to the level of CD20, the target for rituximab, on primary lymphoma cells. While the expression level of CD40 was similar between different samples of primary follicular lymphoma cells, it was 10 fold less than the level of CD20. The expression of CD40 and CD20 on chronic lymphocytic leukemia/small lymphocytic lymphoma cells (CLL/SLL) was more variable. However, the level of CD20 was still significantly higher than the level of CD40 in all samples tested (2.4 to 13 fold). While CHIR-12.12 binds to primary lymphoma cells similarly to several other anti-CD40 antibodies, CHIR-12.12 did not induce proliferation of these primary tumore cells. By contrast, an agonist anti-CD40 antibody induced proliferation of these lymphoma cells up to 6-fold over baseline. To study the ability of CHIR-12.12 to inhibit the CD40-CD40L interaction, we cultured lymphoma cells with CD40L-transfected feeder cells in the presence of control IgG1, CHIR-12.12 or rituximab. In this system, the lymphoma cells proliferate in response to CD40-CD40L interaction. The addition of rituximab did not influence the proliferation. However, CHIR-12.12 inhibited the proliferation of follicular lymphoma and of CLL/SLL cells in a dose-dependent manner. The inhibition was observed with antibody concentration at 1mu g/ml and reached maximum of 90% inhibition at 10 mu g/ml. We then evaluated the ability of CHIR-12.12 to elicite complement-mediated killing or ADCC. In vitro, rituximab induced complement-mediated cytotoxicity, while CHIR-12.12 did not. However, both CHIR-12.12 and rituximab induced effective ADCC of primary follicular lymphoma cells using purified NK cells from a healthy donor. Eventhough the level of CD40 is 10-fold less than the level of CD20 on the cell surface of these tumor cells, CHIR-12.12 induced the same degree of ADCC killing as did rituximab. Thus, this novel antagonist CHIR-12.12 antibody both blocks tumor-stimulatory CD40/CD40L
interaction and mediates ADCC in the presence of a low number of target antigen. Our results support further development of this antibody to treat patients with B cell lymphoma.

2/7/4 (Item 4 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

18234887 BIOSIS NO.: 20050014952
Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival
AUTHOR: Adams Andrew B; Shirasugi Nozomu; Jones Thomas R; Durham Megan M; Strobert Elizabeth A; Cowan Shannon; Rees Phyllis; Hendrix Rose; Price Karen; Kenyon Norma S; Hagerty David; Townsend Robert; Hollenbaugh Dianne; Pearson Thomas C (Reprint); Larsen Christian P
AUTHOR ADDRESS: Dept Surg, Emory Transplant Ctr, Suite 5105, Woodruff Mem Res Bldg, 101 Woodruff Cir, Atlanta, GA, 30332, USA**USA
AUTHOR E-MAIL ADDRESS: tpearson@emoryhealthcare.org; clarsen@emoryhealthcare.org
MEDIUM: print
ISSN: 0022-1767 _(ISSN print)
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: In recent years, reagents have been developed that specifically target signals critical for effective T cell activation and function. Manipulation of the CD28/CD80/86 and CD40/CD154 pathways has exhibited extraordinary efficacy, particularly when the pathways are blocked simultaneously. Despite the reported efficacy of anti-CD154 in rodents and higher models, its future clinical use is uncertain due to reported thromboembolic events in clinical trials. To circumvent this potential complication, we developed and evaluated a chimeric Ab targeting CD40 (Chi220, BMS-224819) as an alternative to CD154. Although Chi220 blocks CD154 binding, it also possesses partial agonist properties and weak stimulatory potential. The anti-CD40 was tested alone. and in combination with a rationally designed, high affinity variant of CTLA4-1g, LEA29Y (belatacept), in a nonhuman primate model of islet transplantation. Although either agent alone only modestly prolonged islet survival (Chi220 alone: 14, 16, and 84 days; LEA29Y alone: 58 and 60 days), their combination (LEA29Y and Chi220) dramatically facilitated long term survival (237, 237, 220, >185, and 172 days). We found that the effects of Chi220 treatment were not mediated solely through deletion of CD20-bearing cells and that the combined therapy did not significantly impair established antiviral immunity.

2/7/5 (Item 5 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

16647704 BIOSIS NO.: 200200241215
Human anti-CD40 antagonistic antibodies inhibit the proliferation of human B cell non-Hodgkin's lymphoma
AUTHOR: Weng Wen-Kai (Reprint); Wang Changyu; Chu Keting; Levy Ronald (Reprint)
AUTHOR ADDRESS: Medicine/Oncology, Stanford University, Stanford, CA, USA**USA
ABSTRACT: CD40 is expressed on the vast majority of the non-Hodgkin's B cell lymphomas. It has been proposed that the CD40/CD40L interaction provides a critical survival or proliferative signal for B cell lymphoma, especially the low-grade follicular lymphoma. In addition, B lymphoma cell lines become less sensitive to chemotherapy-induced apoptosis after CD40 cross-linking in an in vitro study (Walker et al. Cancer Res. 1997, 57:1939), probably via the up-regulation of a death-suppressor protein, BCL-xL. Therefore, a potential therapeutic strategy would be to develop an anti-CD40 blocking antibody (agonist) that could disrupt the CD40/CD40L interaction. Such a reagent could be used alone or in combination with other therapeutic modalities, eg. chemotherapy. In this report, we describe four human anti-CD40 antibodies, 2F5 (IgG) and 15B8 (IgG2) (agonists); 12C3.2 (IgG1) and MS81 (IgG2) (agonists), that were generated from transgenic mice whose immunoglobulin gene locus were replaced with human IgG immunoglobulin gene locus. All four antibodies stain tumor cells from patients with follicular lymphoma to a similar degree. However, while the anti- ***CD40*** ***agonistic*** antibodies up-regulated the cell surface Fas, B7-1, B7-2 and VCAM-1 on follicular lymphoma cells, neither of the two anti-CD40 antagonistic antibodies has any effect on the expression of these molecules. Follicular lymphoma cells isolated from biopsy samples showed minimal proliferative activity when cultured with medium alone. The anti- ***CD40*** ***agonistic*** antibodies induced proliferation of these follicular lymphoma cells up to 10 fold over baseline. In contrast, the antagonistic antibodies 2F5 and 15B8 showed no such effect. In one case, 2F5 inhibited the baseline proliferation of the tumor cells by 70%. We then tested the ability of these two anti-CD40 antagonistic antibodies to interrupt the CD40-CD40L interaction. To study this, we cultured follicular lymphoma cells with CD40L-transfected feeder cells in the presence of different antibodies. In this system, the follicular lymphoma cells proliferate in response to ***CD40*** -CD40L interaction. The addition of control Ig or anti-CD40 agonistic antibodies did not influence the proliferation. However, both 2F5 and 15B8 inhibited the proliferation of lymphoma cells in this system in a dose-dependent manner. The inhibition was more pronounced with 2F5 (maximum 95% inhibition) than with 15B8 (maximum 65% inhibition). This inhibition of CD40L-driven proliferation of tumor cells was observed in all of 6 follicular lymphoma patient samples tested, including 4 samples from patients who were refractory to previous ***Rituximab*** therapy. Inhibition was also observed in one mantle cell lymphoma sample. Additional studies are in progress to evaluate the ability of these two anti-CD40 antagonistic antibodies to elicit complement-mediated and antibody-dependent cellular cytotoxicities, and their potential to use in treating patients with B cell non-Hodgkin's lymphoma.
dependent on binding valency
 AUTHOR: Ledbetter Jeffrey A (Reprint); Grosmaire Laura S; Hollenbaugh Diane ; Aruffo Alejandro; Nadler Steven G
 AUTHOR ADDRESS: Bristol-Myers Squibb, Pharm. Res. Inst., 3005 First Ave.,
 Seattle, WA 98121, USA**USA
 ISSN: 0092-6213
 DOCUMENT TYPE: Article
 RECORD TYPE: Abstract
 LANGUAGE: English

ABSTRACT: CD40 functional responses can be triggered by binding of mAb
G28-5. Here we show that G28-5 induces partial CD40 responses and
functions as a partial antagonist of natural CD40 ligand, gp39, by
preventing gp39 binding. Fab fragments of G28-5 retain inhibitory
activity but lose crosslinking-dependent stimulatory activity. The
synergistic interaction of CD40 signals with PMA or CD20 show
differential requirements for CD40 crosslinking and different sensitivity
to cyclosporine A, suggesting that CD40 receptor may use different
effector mechanisms for synergy with calcium-dependent CD20 signals
or with calcium-independent signals from PMA. Activation of NF-kappa-B
occurred in RAJI cells by G28-5 or by gp39 treatment, and was CD40
crosslinking-dependent. These results suggest that activation of
NF-kappa-B is involved in some CD40 receptor signals and may be related
to CD40 effects on stimulation or inhibition of apoptosis.

0081529562 EMBASE No: 2006593143
Cancer: Novel therapeutic strategies that exploit the TNF-related
apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway
Cretney E.; Takeda K.; Smyth M.J.
Cancer Immunology Program, Trescowthick Research Laboratories, Peter
MacCallum Cancer Centre, East Melbourne, Vic. 3002, Australia
AUTHOR EMAIL: mark.smyth@petermac.org
CORRESP. AUTHOR/AFFIL: Smyth M.J.: Cancer Immunology Program,
Trescowthick Research Laboratories, Peter MacCallum Cancer Centre, East
Melbourne, Vic. 3002, Australia
CORRESP. AUTHOR EMAIL: mark.smyth@petermac.org

Cell Biol.) (United Kingdom) January 15, 2007, 39/2 (280-286)
CODEN: IJBBF ISSN: 1357-2725
PUBLISHER ITEM IDENTIFIER: S1357272506002792
DOI: 10.1016/j.biocel.2006.10.005
DOCUMENT TYPE: Journal; Short Survey RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 44
Cancer is a widespread disease, with half of all men and one-third of all
women in the United States developing cancer during their lifetime. The
efficacy of many cancer treatments including radiotherapy, chemotherapy and
immunotherapy is due to their ability to induce tumor cell apoptosis.
Recombinant tumor necrosis factor (TNF)-related apoptosis-inducing ligand
(TRAIL) is currently being developed as a cancer therapeutic since it
selectively induces apoptosis in a variety of transformed cells, but not in
most normal cells. Agonistic monoclonal antibodies (mAbs) specific for
human death-inducing TRAIL receptors (DR4 or DR5) are also being actively
pursued. Importantly, in experimental mice, synergistic anti-tumor effects
have been observed with a combination treatment of agonistic mAb against
DR5 together with either IL-21 or agonistic mAbs against CD40
and CD137. Together, these findings suggest that antibody-based therapies
that cause tumor cell apoptosis and promote T cell memory or function may
be effective in fighting cancer. Crown Copyright (c) 2006.

2/7/8 (Item 2 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0077090181  EMBASE No: 1997383451
Agonistic activity of a CD40-specific single-chain Fv
constructed from the variable regions of mAb G28-5
Ledbetter J.A.; Francisco J.A.; Siegall C.B.; Gilliland L.K.; Hollenbaugh
D.; Aruffo A.; Siadak A.W.; Mischel-Petty N.; Grosmaire L.S.; Gordon M.L.;
Brown T.J.; Moran-Davis P.; Mittler R.S.; Kiener P.A.; Nadler S.G.
Bristol-Myers Squibb P., 3005 First Avenue, Seattle, WA 98121, United
States
CORRESP. AUTHOR/AFFIL: Nadler S.G.: BMS Pharmaceut. Research Institute,
3005 First Avenue, Seattle, WA 98121, United States

Critical Reviews in Immunology ( CRIT. REV. IMMUNOL. ) (United States)
December 1, 1997, 17/5-6 (427-435)
CODEN: CCRID  ISSN: 1040-8401
DOCUMENT TYPE: Journal; Conference Paper RECORD TYPE: Abstract
LANGUAGE: English  SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 26

A single-chain Fv (scFv) was expressed from the variable regions of the
CD40-specific mAb (328-5). The molecule bound CD40 with a high affinity (2.2
nM) and was a monomer in solution. Surprisingly, G28-5 scFv was a potent
CD40 agonist that rapidly crosslinked CD40 on the cell
surface but did not crosslink CD4-Ig in solution. G28-5 scFv was a more
potent agonist than G28-5 IgG and was able to stimulate CD40
responses by B cells and monocytes. G28-5 IgG partially blocked, whereas
G28-5 scFv augmented CD40 responses during stimulation with natural ligand
(gp39-CO8 fusion protein). These results indicate that the functional
activity of ligands built from the binding site of G28-5 is highly
dependent upon the size and physical properties of the molecule both in
solution and on the cell surface.

? s (cd40)(10n)(antibod? or immunoglobulin?) and (cd20 or rituxan or rituximab)
34908  CD40
2338190  ANTIBOD?
884163  IMMUNOGLOBULIN?
7673  CD40(10N)(ANTIBOD? OR IMMUNOGLOBULIN?)
21687  CD20
1876  RITUXAN
20705  RITUXIMAB
S3  434  (CD40)(10N)(ANTIBOD? OR IMMUNOGLOBULIN?) AND (CD20 OR
RITUXAN OR RITUXIMAB)
? s s3 and (cancer? or tumor? or neoplas? or tumour? or leukemi? or lymphoma?)
Processing
434  S3
3028776  CANCER?
3189463  TUMOR?
3114698  NEOPLAS?
379571  TUMOUR?
701810  LEUKEMI?
400997  LYMPHOMA?
S4  280  S3 AND (CANCER? OR TUMOR? OR NEOPLAS? OR TUMOUR? OR
LEUKEMI? OR LYMPHOMA?)

? rd s4
S5  241  RD S4 (unique items)
? s s5 and (cd40)(20n)(agonist? or stimulat? or increas?)
>>>Unmatched parentheses
? s s5 and (cd40)(20n)(agonist? or stimulat? or increas?)
Processing
241  S5
   34908  CD40
   589238  AGONIST?
   2742672  STIMULAT?
   7853004  INCREAS?
   9496  CD40(20N)((AGONIST? OR STIMULAT?) OR INCREAS?)
S6  24  S5 AND (CD40)(20N)(AGONIST? OR STIMULAT? OR INCREAS?)
? rd s6
S7  24  RD S6 (unique items)
? t s7/3/all

7/3/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

0020168862  BIOSIS NO.: 200800215801
hCD122, an antagonist human Anti-CD40 monoclonal antibody,
   enhances efficacy of CHOP in tumor xenograft model of human diffuse
   large B-Cell ***lymphoma*** .
AUTHOR: Lugman Mohammad (Reprint); Hsu Ssucheng J; Ericson Matthew;
   Klabunde Sha; Kantak Seema
AUTHOR ADDRESS: Inst Biomed Res, Emeryville, CA USA**USA
CONFERENCE/MEETING: 49th Annual Meeting of the
American-Society-of-Hematology Atlanta, GA, USA December 08 -11, 2007;
20071208
SPONSOR: Amer Soc Hematol
ISSN: 0006-4971
DOCUMENT TYPE: Meeting; Meeting Abstract
RECORD TYPE: Abstract
LANGUAGE: English

7/3/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

0019597945  BIOSIS NO.: 200700257686
Delayed redistribution of CD27, CD40 and CD80 positive B cells and
   the impaired in vitro immunoglobulin G production in patients with
   non-hodgkin ***lymphoma*** treated with ***rituximab*** .
AUTHOR: Nishio Mitsufumi (Reprint); Fujimoto Katsuya; Yamamoto Satoshi;
   Sakai Toshiya; Kumanohohi Koki; Obara Masato; Koizumi Kazuki; Mukai Masaya;
   Sato Norihiro; Koike Takao
AUTHOR ADDRESS: Hokkaido Univ, Grad Sch Med, Sapporo, Hokkaido, Japan**
   Japan
CONFERENCE/MEETING: 48th Annual Meeting of the
American-Society-of-Hematology Orlando, FL, USA December 09 -12, 2006;
20061209
SPONSOR: Amer Soc Hematol
ISSN: 0006-4971
DOCUMENT TYPE: Meeting; Meeting Poster
RECORD TYPE: Abstract
Humanized anti CD-40 antibody SGN-40 effectively induces cytotoxicity against chronic lymphocytic leukemia (CLL) cells through antibody mediated cytotoxicity and demonstrates modest biologic evidence of CD40 activation

AUTHOR: Gowda Aruna C (Reprint); Zhao Xiaobin B; Cheney Carolyn; Mehter Najma; Lozanski Gerard; Lin Thomas S; Guster Sara; Drachman J G; Muthusamy Natarajan; Byrd John C

AUTHOR ADDRESS: Ohio State Univ, Columbus, OH 43210 USA**USA


SPONSOR: Amer Soc Hematol

ISSN: 0006-4971

DOCUMENT TYPE: Meeting; Meeting Poster

RECORD TYPE: Abstract

LANGUAGE: English
7/3/6 (Item 6 from file: 5)
DIALOG(R)File  5:Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

18575974  BIOSIS NO.: 200510270474
In vitro activity of a novel fully human anti-CD40 antibody
CHIR-12.12 in chronic lymphocytic ***leukemia*** : Blockade of ***CD40***
activation and induction of ADCC.
AUTHOR: Tong Xia (Reprint); Georgakis Georgios V; Li Long; Susan O'Brien;
Aas Yunes; Mohammad Luqman
AUTHOR ADDRESS: Chiron Corp. Res and Dev, Emeryville, CA 94608 USA**USA
CONFERENCE/MEETING: 46th Annual Meeting of the
American-Society-of-Hematology San Diego, CA, USA December 04 -07, 2004;
20041204
SPONSOR: Amer Soc Hematol
ISSN: 0006-4971
DOCUMENT TYPE: Meeting; Meeting Poster
RECORD TYPE: Abstract
LANGUAGE: English

7/3/7 (Item 7 from file: 5)
DIALOG(R)File  5:Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

18575884  BIOSIS NO.: 200510270384
A fully human antagonist anti-CD40 antibody triggers
significant antitumor activity against human multiple myeloma
AUTHOR: Tai Yu-Tzu (Reprint); Li Xian-Feng; Tong Xia; Catley Laurence;
Santos Daniel; Tournilhac Olivier; Schlossman Robert; Richardson Paul;
Munshi Nikhil C; Luqman Mohammad; Anderson Kenneth C
AUTHOR ADDRESS: Dana Farber Canc Inst, Dept Med Oncol, Jerome Lipper
Multiple Myeloma Ctr, Boston, MA 02115 USA**USA
CONFERENCE/MEETING: 46th Annual Meeting of the
American-Society-of-Hematology San Diego, CA, USA December 04 -07, 2004;
20041204
SPONSOR: Amer Soc Hematol
ISSN: 0006-4971
DOCUMENT TYPE: Meeting; Meeting Poster
RECORD TYPE: Abstract
LANGUAGE: English

7/3/8 (Item 8 from file: 5)
DIALOG(R)File  5:Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

18572914  BIOSIS NO.: 200510267414
Regulation of Berg-36 gene expression by survival and apoptotic stimuli in
B-chronic lymphocytic leukaemia cells.
AUTHOR: Jewell Andrew P (Reprint); Baou Maria; Yong Kwee L; Carr Robert;
Murphy John
AUTHOR ADDRESS: Kingston Univ, Kingston upon Thames KT1 2EE, Surrey, UK**UK
Comparative efficacy of Rituximab and a fully human anti-CD40 antagonist antibody in vitro and in xenograft lymphoma models.

AUTHOR: Long Li (Reprint); Tong Xia (Reprint); Patawaran Montesa (Reprint); Luqman Mohammad (Reprint)

AUTHOR ADDRESS: Research, Chiron Corporation, Emeryville, CA, USA**USA


MEDIUM: print

CONFERENCE/MEETING: 45th Annual Meeting of the American Society of Hematology San Diego, CA, USA December 06-09, 2003; 20031206

SPONSOR: American Society of Hematology

ISSN: 0006-4971

DOCUMENT TYPE: Meeting; Meeting Poster; Meeting Abstract

RECORD TYPE: Abstract

LANGUAGE: English

Human anti-CD40 antagonistic antibodies inhibit the proliferation of human B cell non-Hodgkin's lymphoma

AUTHOR: Weng Wen-Kai (Reprint); Wang Changyu; Chu Keting; Levy Ronald (Reprint)

AUTHOR ADDRESS: Medicine/Oncology, Stanford University, Stanford, CA, USA** USA


MEDIUM: print

CONFERENCE/MEETING: 43rd Annual Meeting of the American Society of Hematology, Part 1 Orlando, Florida, USA December 07-11, 2001; 20011207

SPONSOR: American Society of Hematology

ISSN: 0006-4971

DOCUMENT TYPE: Meeting; Meeting Abstract

RECORD TYPE: Abstract

LANGUAGE: English

Increased inhibition of proliferation of human B cell lymphomas
following ligation of CD40, and either CD19, CD20, CD95 or surface immunoglobulin

AUTHOR: Benoit Nicole E; Wade William F (Reprint)
AUTHOR ADDRESS: Dep. Microbiol., Dartmouth Med. Sch., Lebanon, NH 03756, USA*USA
ISSN: 0162-3109
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

7/3/12 (Item 12 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

13000597 BIOSIS NO.: 199598468430
Antibodies to CD40 prevent Epstein-Barr virus-mediated human
B-cell lymphomagenesis in severe combined immune deficient mice
given human peripheral blood lymphocytes
AUTHOR: Murphy William J (Reprint); Funakoshi Satoshi; Beckwith Margaret;
Rushing Susan E; Conley Denise K; Armitage Richard J; Fanslow William C;
Rager Helen C; Taub Dennis D; Ruscetti Francis W; Longo Dan L
AUTHOR ADDRESS: Biol. Carcinogenesis and Dev. Program, Program Resources
Inc./DynCorp, NCI-FDRC, Build. 567, Room 141, Frederick, MD 21702-1201, USA*USA
ISSN: 0006-4971
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

7/3/13 (Item 13 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

11307186 BIOSIS NO.: 199294009027
IL-4 INDUCES CONFORMATIONAL CHANGE OF CD20 ANTIGEN VIA A PROTEIN
KINASE C-INDEPENDENT PATHWAY ANTAGONISTIC EFFECT OF ANTI-CD40
MONOCLONAL ANTIBODY
AUTHOR: DANCESCU M (Reprint); WU C; RUBIO M; DELESPESSE G; SARPATI M
AUTHOR ADDRESS: ALLERGY RES LAB, NOTRE-DAME HOSP RES CENT, 1560 SHERBROOKE
ST EAST, MONTREAL, QUE H2L 4M1*CANADA
ISSN: 0022-1767
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

7/3/14 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0081529562 EMBASE No: 2006593143
Cancer: Novel therapeutic strategies that exploit the TNF-related
apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway
Cretney E.; Takeda K.; Smyth M.J.
Cancer Immunology Program, Trescowthick Research Laboratories, Peter
MacCallum Cancer Centre, East Melbourne, Vic. 3002, Australia
New treatments for SLE: Cell-depleting and anti-cytokine therapies
Anolik J.H.; Aringer M.
Allergy, Immunology and Rheumatology Unit, Department of Medicine,
University of Rochester School of Medicine and Dentistry, Rochester, NY
14642, United States
AUTHOR EMAIL: jennifer; anolik@urmc.rochester.edu
CORRESP. AUTHOR/AFFILI: Anolik J.H.: Allergy, Immunology and Rheumatology
Unit, Department of Medicine, University of Rochester School of Medicine
and Dentistry, Rochester, NY 14642, United States
CORRESP. AUTHOR EMAIL: jennifer; anolik@urmc.rochester.edu

Fc receptor targeting in the treatment of allergy, autoimmune diseases
and cancer
Nakamura A.; Akiyama K.; Takai T.
Tohoku University, Dept. of Experimental Immunology, Inst. of Development
Ageing/Cancer, Seiryo 4-1, Sendai 980-8575, Japan
AUTHOR EMAIL: aki@idac.tohoku.ac.jp
CORRESP. AUTHOR/AFFILI: Nakamura A.: Tohoku University, Dept. of
Experimental Immunology, Inst. of Development Ageing/Cancer, Seiryo 4-1,
Sendai 980-8575, Japan
CORRESP. AUTHOR EMAIL: aki@idac.tohoku.ac.jp

Expert Opinion on Therapeutic Targets (Expert Opin. Ther. Targets) (United Kingdom) February 1, 2005, 9/1 (169-190)
7/3/17  (Item 4 from file: 73)
DIALOG(R)File  '73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0076676499  EMBASE No: 1996352908
Increased inhibition of proliferation of human B cell
lymphomas following ligation of CD40, and ishter CD19,
CD20, CD95 or surface immunoglobulin
Benoit N.E.; Wade W.F.
Department of Microbiology, Dartmouth Medical School, Lebanon, NH 03756,
United States
AUTHOR EMAIL: william.wade@dartmouth.edu
CORRESP. AUTHOR/AFFIL: Wade W.F.: Department of Microbiology, Dartmouth
Medical School, Lebanon, NH 03756, United States

Immunopharmacology ( IMMUNOPHARMACOLOGY ) (Netherlands) November 1, 1996,
35/2 (129-139)
PUBLISHER ITEM IDENTIFIER: 50162310996001385
DOI: 10.1016/S0162-3109(96)00138-5
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 33

7/3/18  (Item 5 from file: 73)
DIALOG(R)File  '73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0075416581  EMBASE No: 1993196137
CD40 plays an essential role in the activation of human B cells by murine
EL4B5 cells
Kwekkeboom J.; De Boer M.; Tager J.M.; De Groot C.
Lab. of Cell Biology and Histology, University of Amsterdam, Academic
Medical Center, Meibergdreef 15, 1105 AZ Amsterdam, Netherlands
CORRESP. AUTHOR/AFFIL: Kwekkeboom J.: Lab. of Cell Biology and Histology,
University of Amsterdam, Academic Medical Center, Meibergdreef 15, 1105 AZ
Amsterdam, Netherlands

Immunology ( IMMUNOLOGY ) (United Kingdom) July 28, 1993, 79/3 (439-444)
CODEN: IMMUA ISSN: 0019-2805
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English

7/3/19  (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2008 Dialog. All rts. reserv.

14671788  PMID: 12072193
CM1 ligation initiates apoptosis in a caspase 8-dependent manner in Ramos
cells and in a mitochondria-controlled manner in Raji cells.
Kim Daejin; Hur Dae Young; Kim Yeong Seok; Lee Kyungmi; Lee Youngseon;
Cho Daeho; Kang Jae Seung; Kim Young-in; Hahm Eunsil; Yang Yoolhee; Yoon
Expression of CD40/CD40 ligand and Bcl-2 family proteins in labial salivary glands of patients with Sjogren's syndrome.

Nakamura H; Kawakami A; Tominaga M; Migita K; Kawabe Y; Nakamura T; Eguchi K
First Department of Internal Medicine, Nagasaki University School of Medicine, Nagasaki City, Japan.

Laboratory investigation; a journal of technical methods and pathology (UNITED STATES) Mar 1999, 79 (3) p261-9, ISSN 0023-6837--Print

Use of stimulatory anti-CD40 antibodies in the treatment of diseases associated with aberrant CD40 presentation on cell surfaces

INVENTOR(AUTHOR): Drachman, Jonathan; Law, Che-Leung; Lewis, Tim

LOCATION: USA

ASSIGNEE: Seattle Genetics, Inc.

PATENT: PCT International; WO 200675326 A2 DATE: 20070705
PAGES: 125pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

DESIGNATED COUNTRIES: AB; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; GT; HN; HR; HU; ID; IL; IN; IS; JP; KL; KG; KM; KN; KP; KR; KZ; LA; LC; LL; LS; LT; LU; LV; LY; MA; MD; MG; MK; MN; MW; MX; MY; MZ; NA; NG; NI; NO; NZ; OM; PB; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG; SK; SL; SM; SV; SY; TJ; TM; TN; TR; TT; TZ; UA; US DESIGNATED REGIONAL: AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; IE; IS; IT; LT; LU; LV; MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML;
7/3/22 (Item 2 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2008 American Chemical Society. All rts. reserv.

144231465 CA: 144(13)231465p PATENT
Humanized antibodies with Man3GlcNAc2 modification to increase
FcyRIII receptor binding and ADCC for therapeutic use
INVENTOR(AUTHOR): Gerngross, Tillman U.; Li, Huijuan; Wildt, Stefan
LOCATION: USA
(20040721) *US 2005500240 (20050323)
PAGES: 47 pp., Cont.-in-part of U.S. Ser. No. 500,240. CODEN: USXXCO
LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: 424130100
IPCR/8 + Level Value Position Status Version Action Source Office:
C07K-0016/28 A I F B 20060101 20060216 H US
C07H-0021/04 A I L B 20060101 20060216 H US
C12P-0021/06 A I L B 20060101 20060216 H US
A61K-0039/395 A I L B 20060101 20060216 H US
C12N-0005/06 A I L B 20060101 20060216 H US

7/3/23 (Item 3 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2008 American Chemical Society. All rts. reserv.

144005405 CA: 144(1)5405n PATENT
Antibody glycosylation variants having increased antibody-dependent
cellular cytotoxicity
INVENTOR(AUTHOR): Umana, Pablo; Jean-Mairet, Joel; Bailey, James E.
LOCATION: Switz.
ASSIGNEE: Glycart Biotechnology AG
APPLICATION: US 2005199232 (20050809) *US 2002211554 (20020805) *US
2003633697 (20030805)
PAGES: 28 pp., Cont.-in-part of U.S. Ser. No. 633,697. CODEN: USXXCO
LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: 435069100; C07K-016/28A; C07H-021/04B; C12P-021/06B;
C12N-005/06B

7/3/24 (Item 4 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2008 American Chemical Society. All rts. reserv.

141172878 CA: 141(11)72878p PATENT
Engineering of glycosylation profile of antibody Fc region to increase Fc
receptor binding affinity and effector function for treating cancer
INVENTOR(AUTHOR): Umana, Pablo; Bruenker, Peter; Ferrara, Claudia; Suter, Tobias
LOCATION: Switz.
ASSIGNEE: Glycart Biotechnology AG
PATENT: PCT International; WO 200465540 A2 DATE: 20040805
Increased inhibition of proliferation of human B cell lymphomas following ligation of CD40, and isheer CD19, CD20, CD95 or surface immunoglobulin

Benoit N.E.; Wade W.F.
Department of Microbiology, Dartmouth Medical School, Lebanon, NH 03756, United States

AUTHOR EMAIL: william.wade@dartmouth.edu
CORRESP. AUTHOR/AFFIL: Wade W.F.: Department of Microbiology, Dartmouth Medical School, Lebanon, NH 03756, United States

Immuno pharmacology ( IMMUNOPHARMACOLOGY ) (Netherlands) November 1, 1996, 35/2 (129-139)
CODEN: IMMUD ISSN: 0162-3109
PUBLISHER ITEM IDENTIFIER: S0162310996001385
DOI: 10.1016/S0162-3109(96)00138-5
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 33

Non-Hodgkin's (NHL) B cell lymphomas are growth-inhibited by ligation of their CD40 molecules. This inhibition is not absolute in that ~50% of the cells are not inhibited. We conducted studies to see if other signals that have been reported to inhibit B cell lymphoma growth could be used in combination with anti-CD40 signaling to completely inhibit growth. Ligation of surface ***immunoglobulin*** (Ig), CD19, CD20, CD37 or CD95 with soluble antibody did not affect growth of the panel of NHL cells examined. Ligation of ***CD20***, CD19 or CD95 was inhibitory for some NHL cell lines if the primary antibody was crosslinked with a secondary ***antibody***. Combining anti- ***CD40*** with anti-CD19, anti-CD20, or anti-Ig resulted in increased inhibition past that produced by anti- ***CD40*** alone. The additive effect of anti-CD40 and other antibodies to selected surface markers was not observed in all NHL cell lines. Crosslinking of CD95 was also growth inhibitory for the majority of the NHL, and when combined with anti-CD40 under conditions that afforded crosslinking of the two receptors, increased inhibition was seen in three of the NHL cell lines. We found that cAMP or sodium butyrate (NaB) were also effective at inhibiting growth of the NHL cells; this was a profound inhibition (approaching 100%) compared to the 50% inhibition seen with anti-CD40 treatment. The potential for anti-CD40 and either cAMP or NaB to be additive was tested and not found to be the case. The ability to inhibit proliferation of the NHL was very dynamic with some antibody combinations being either inhibitory for multiple cells, not having an effect at all, or
in some cases being stimulatory. This suggests that the NHL may represent
unique stages of B cells that might serve as a model system which could be
developed to precisely categorize patient NHL.

? ds

<table>
<thead>
<tr>
<th>Set</th>
<th>Items</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>S1</td>
<td>15</td>
<td>(CD40)(10N)(AGONIST?) AND (CD20 OR RITUXAN OR RITUXIMAB)</td>
</tr>
<tr>
<td>S2</td>
<td>9</td>
<td>RD S1 (unique items)</td>
</tr>
</tbody>
</table>
| S3  | 434   | (CD40)(10N)(ANTIBOD? OR IMMUNOGLOBULIN?) AND (CD20 OR RITU-
XAN OR RITUXIMAB) |
| S4  | 280   | S3 AND (CANCER? OR TUMOR? OR NEOPLAS? OR TUMOUR? OR LEUKEM-
I? OR LYMPHOMA?) |
| S5  | 241   | RD S4 (unique items) |
| S6  | 24    | S5 AND (CD40)(20N)(AGONIST? OR STIMULAT? OR INCREAS?) |
| S7  | 24    | RD S6 (unique items) |

? s s (cd40?)(20n)(agonist? or stimulat? or increas?) and (cd20 or rituxan or
rituximab)
Processing

<table>
<thead>
<tr>
<th>0</th>
<th>S (CD40)?</th>
</tr>
</thead>
<tbody>
<tr>
<td>589238</td>
<td>AGONIST?</td>
</tr>
<tr>
<td>2742672</td>
<td>STIMULAT?</td>
</tr>
<tr>
<td>7853004</td>
<td>INCREAS?</td>
</tr>
<tr>
<td>0</td>
<td>S (CD40?)(20N)((AGONIST? OR STIMULAT?) OR INCREAS?)</td>
</tr>
<tr>
<td>21687</td>
<td>CD20</td>
</tr>
<tr>
<td>1876</td>
<td>RITUXAN</td>
</tr>
<tr>
<td>20705</td>
<td>RITUXIMAB</td>
</tr>
</tbody>
</table>

? s (cd40?)(20n)(agonist? or stimulat? or increas?) and (cd20 or rituxan or
rituximab)

| 36447 | CD40? |
| 589238 | AGONIST? |
| 2742672 | STIMULAT? |
| 7853004 | INCREAS? |
| 10844 | CD40?(20N)((AGONIST? OR STIMULAT?) OR INCREAS?) |
| 21687 | CD20 |
| 1876  | RITUXAN |
| 20705 | RITUXIMAB |

? rd s9

| 105 | RD S9 (unique items) |

? s s10 and(tumor? or tumour? or cancer? or neoplas? or leukemi? or lymphoma?)
Processing

| 105 | S10 |
| 3189463 | TUMOR? |
| 379571 | TUMOUR? |
| 3028776 | CANCER? |
| 3114698 | NEOPLAS? |
| 701810 | LEUKEMI? |
| 400997 | LYMPHOMA? |

| 57 | S10 AND(TUMOR? OR TUMOUR? OR CANCER? OR NEOPLAS? OR LEUKEMI? OR LYMPHOMA?) |

? rd s11

| 57 | RD S11 (unique items) |

? t s12/3/all

12/3/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.
0020168862  BIOSIS NO.: 200800215801
hCD122, an antagonist human Anti-CD40 monoclonal antibody, enhances
 efficacy of CHOP in tumor xenograft model of human diffuse large
 B-Cell ***lymphoma**

AUTHOR: Lugman Mohammad (Reprint); Hsu Ssucheng J; Ericson Matthew;
 Klabunde Sha; Kantak Seema
AUTHOR ADDRESS: Inst Biomed Res, Emeryville, CA USA**USA
CONFERENCE/MEETING: 49th Annual Meeting of the
American-Society-of-Hematology Atlanta, GA, USA December 08 -11, 2007;
20071208
SPONSOR: Amer Soc Hematol
ISSN: 0006-4971
DOCUMENT TYPE: Meeting; Meeting Abstract
RECORD TYPE: Abstract
LANGUAGE: English

12/3/2  (Item 2 from file: 5)
DIALOG(R)File  5:Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

0019597945  BIOSIS NO.: 200700257686
Delayed redistribution of CD27, CD40 and CD80 positive B cells and the
 impaired in vitro immunoglobulin G production in patients with
 non-hodgkin ***lymphoma*** treated with ***rituximab***

AUTHOR: Nishio Mitsufumi (Reprint); Fujimoto Katsuya; Yamamoto Satoshi;
 Sakai Toshiya; Kumano Kohki; Obara Masato; Koizumi Kazuki; Mukai Masaya;
 Sato Norihiro; Koike Takao
AUTHOR ADDRESS: Hokkaido Univ, Grad Sch Med, Sapporo, Hokkaido, Japan**
 Japan
CONFERENCE/MEETING: 48th Annual Meeting of the
American-Society-of-Hematology Orlando, FL, USA December 09 -12, 2006;
20061209
SPONSOR: Amer Soc Hematol
ISSN: 0006-4971
DOCUMENT TYPE: Meeting; Meeting Poster
RECORD TYPE: Abstract
LANGUAGE: English

12/3/3  (Item 3 from file: 5)
DIALOG(R)File  5:Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

0019586341  BIOSIS NO.: 200700246082
Involvement of the Tis11b/Berg36 family in the regulation of B-CLL
 survival and differentiation.

AUTHOR: Başu Maria (Reprint); Murphy John; Yong Kwee L; Carr Robert; Jewell
 Andrew P
AUTHOR ADDRESS: Univ London Imperial Coll Sci and Technol, London, UK**UK
CONFERENCE/MEETING: Symposium of the
International-Society-of-Molecular-Evolution GUANANACASTE, COSTA RICA
January 08 -12, 2001; 20010108
SPONSOR: Int Soc Molec Evolut
ISSN: 0006-4971
DOCUMENT TYPE: Meeting; Meeting Abstract
RECORD TYPE: Abstract
LANGUAGE: English
12/3/4
12/3/5
12/3/6

Dysregulation of TNF/TNF receptor superfamily members: A systemic link between intra- and extrathyroidal manifestations in Graves' disease

AUTHOR: Quadbeck B; Stucke M; Eckstein A K; Heise D J; Mann K; Gieseler R K
Reprint
AUTHOR ADDRESS: LETI Pharma GmbH, Div R and D, Mannesmannstr 4, D-58455 Witten, Germany**Germany
AUTHOR E-MAIL ADDRESS: gieseler@leti.de
ISSN: 0300-9475
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

Humanized anti CD-40 antibody SGN-40 effectively induces cytotoxicity against chronic lymphocytic leukemia (CLL) cells through antibody mediated cytotoxicity and demonstrates modest biologic evidence of CD40 activation

AUTHOR: Gowda Aruna C (Reprint); Zhao Xiaobin B; Cheney Carolyn; Mehter Najma; Lozanski Gerard; Lin Thomas S; Guster Sara; Drachman J G; Muthusamy Natarajan; Byrd John C
AUTHOR ADDRESS: Ohio State Univ, Columbus, OH 43210 USA**USA
SPONSOR: Amer Soc Hematol
ISSN: 0006-4971
DOCUMENT TYPE: Meeting; Meeting Poster
RECORD TYPE: Abstract
LANGUAGE: English

A non-internalizing anti-CD40 antibody, CHIR-12.12, blocks CD40L-induced cytokine production and mediates greater ADCC than rituximab in primary CLL cells

AUTHOR: Tong Xia (Reprint); Aukerman Sharon Lea; Lin Karen; Aziz Natasha; Goldbeck Cheryl; Georgakis Georgios V; Younes Anas; Weng Wen-Kai; O'Brien Susan; Wierda William; Jallal Bahija; Luqman Mohammad
AUTHOR ADDRESS: Chiron Corp, BioPharm Res, Emeryville, CA 94608 USA**USA
Bone marrow mast cells are significantly increased in patients with Waldenstrom's Macroglobulinemia, and their number following therapeutic intervention is dependent on extent of response.

AUTHOR: Santos Daniel Ditziel (Reprint); Chemaly Mariana Z A; Tournilhac Olivier; O'Connor Kelly E; Hatjiharissi Evdokia; Leleu Xavier; Xu Lian; Branagan Andrew R; Manning Robert J; Patterson Christopher; Ho Allen W; Hunter Zachary R; Tai Yu-Tzu; You James M; Kutok Jeffery L; Anderson Kenneth C; Munshi Nikhil; Treon Steven P

AUTHOR ADDRESS: Dana Farber Canc Inst, Bing Ctr Waldenstroms Macroglobulinemia, Boston, MA 02115 USA**USA


Establishment of a Waldenstrom's Macroglobulinemia cell line (BCWM.1) with productive in vivo engraftment in SCID-hu mice

AUTHOR: Santos Daniel Ditziel (Reprint); Ho Allen W; Tournilhac Olivier; Leleu Xavier; Hatjiharissi Evdokia; Xu Lian; Tassone Pierfrancesco; Neri Paola; Hunter Zachary; Chemaly Mariana A Z; Branagan Andrew; Manning Robert; Patterson Christopher; Adania Sophia; Kriangkum Jitra; Kutok Jeffery L; Pilarski Linda; Anderson Kenneth C; Munshi Nikhil; Treon Steven P

AUTHOR ADDRESS: Dana Farber Canc Inst, Bing Ctr Waldenstroms Macroglobulinemia, Boston, MA 02115 USA**USA


Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40

AUTHOR: Law Che-Leung (Reprint); Gordon Kristine A; Collier John; Klussman Kerry; McCaughan Julie A; Cerveny Charles G; Mixan Bruce J; Lee Wyne P; Lin Zhonghua; Valdez Patricia; Wahl Alan F; Grewal Iqbal S

AUTHOR ADDRESS: Seattle Genet Inc, 21823 30th Dr SE, Bothell, WA 98021 USA

AUTHOR E-MAIL ADDRESS: claw@seagen.com


ISSN: 0008-5472

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

A fully human anti-CD40 antagonistic antibody, CHIR-12.12, inhibit the proliferation of human B cell non-Hodgkin's lymphoma

AUTHOR: Weng Wen-Kai (Reprint); Tong Xia; Luqman Mohammad; Levy Ronald

AUTHOR ADDRESS: Stanford Univ, Sch Med, Stanford, CA 94305 USA


CONFERENCE/MEETING: 46th Annual Meeting of the American-Society-of-Hematology San Diego, CA, USA December 04 -07, 2004; 20041204

SPONSOR: Amer Soc Hematol

ISSN: 0006-4971

DOCUMENT TYPE: Meeting; Meeting Poster

RECORD TYPE: Abstract

LANGUAGE: English

In vitro activity of a novel fully human anti-CD40 antibody CHIR-12.12 in chronic lymphocytic leukemia: Blockade of CD40 activation and induction of ADCC.

AUTHOR: Tong Xia (Reprint); Georgakis Georgios V; Li Long; Susan O'Brien; Anas Younes; Mohammad Luqman

AUTHOR ADDRESS: Chiron Corp, Res and Dev, Emeryville, CA 94608 USA


CONFERENCE/MEETING: 46th Annual Meeting of the American-Society-of-Hematology San Diego, CA, USA December 04 -07, 2004; 20041204

SPONSOR: Amer Soc Hematol

ISSN: 0006-4971

DOCUMENT TYPE: Meeting; Meeting Poster

RECORD TYPE: Abstract

LANGUAGE: English
A fully human antagonist anti-CD40 antibody triggers significant antitumor activity against human multiple myeloma

AUTHOR: Tai Yu-Tzu (Reprint); Li Xian-Feng; Tong Xia; Catley Laurence; Santos Daniel; Tournilhac Olivier; Schlossman Robert; Richardson Paul; Munshi Nikhil C; Lugman Mohammad; Anderson Kenneth C

AUTHOR ADDRESS: Dana Farber Canc Inst, Dept Med Oncol, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA**USA


CONFERENCE/MEETING: 46th Annual Meeting of the American-Society-of-Hematology San Diego, CA, USA December 04 -07, 2004; 20041204

SPONSOR: Amer Soc Hematol

ISSN: 0006-4971

DOCUMENT TYPE: Meeting; Meeting Poster

RECORD TYPE: Abstract

LANGUAGE: English

Generation of anti-leukemia reactive T-cells by costimulation with established B-ALL cell lines expressing costimulatory molecules

AUTHOR: Yan Ying (Reprint); Steiherz Peter; Ruan Jianda; Chen Yibang; Abhyankar Sunil; Guan Xiuqin; Williams Casey; Belt Robert; McGuirk Joseph

AUTHOR ADDRESS: UMKC, Canc Inst Kansas City, Sch Med, Leukemia Lymphoma Program, Kansas City, MO USA**USA


CONFERENCE/MEETING: 46th Annual Meeting of the American-Society-of-Hematology San Diego, CA, USA December 04 -07, 2004; 20041204

SPONSOR: Amer Soc Hematol

ISSN: 0006-4971

DOCUMENT TYPE: Meeting; Meeting Abstract

RECORD TYPE: Abstract

LANGUAGE: English

Regulation of Berg-36 gene expression by survival and apoptotic stimuli in B-chronic lymphocytic leukaemia cells.

AUTHOR: Jewell Andrew P (Reprint); Baou Maria; Yong Kwee L; Carr Robert; Murphy John

AUTHOR ADDRESS: Kingston Univ, Kingston upon Thames KT1 2EE, Surrey, UK**UK


CONFERENCE/MEETING: 46th Annual Meeting of the American-Society-of-Hematology San Diego, CA, USA December 04 -07, 2004; 20041204

SPONSOR: Amer Soc Hematol

ISSN: 0006-4971

DOCUMENT TYPE: Meeting; Meeting Abstract
12/3/15  (Item 15 from file: 5)
DIALOG(R)File  5:Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

18442500  BIOSIS NO.: 200510137000
Mitogen induced activation, proliferation and surface antigen expression patterns in unmutated and hypermutated chronic lymphocytic leukemia cells
AUTHOR: Vilpo Juhani (Reprint); Tobin Gerard; Hulkonen Janne; Hurme Mikko; Thunberg Ulf; Sundström Christer; Vilpo Leena; Rosenquist Richard
AUTHOR ADDRESS: PÅciuksenkatu 6 A 4, Helsinki 00290, Finland**Finland
AUTHOR E-MAIL ADDRESS: medivil@kolumbus.fi
ISSN: 0902-4441
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

12/3/16  (Item 16 from file: 5)
DIALOG(R)File  5:Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

18128719  BIOSIS NO.: 200500035784
Improved access to CD20 following B cell receptor cross-linking at Burkitt's lymphoma cell surfaces
AUTHOR: Holder Michelle J; Chamba Anita; Hardie Debbie L; Deans Julie P; Gordon John (Reprint)
AUTHOR ADDRESS: Sch MedWRCCtr Immune Regulat, Univ Birmingham, Vincent Dr, Birmingham, W Midlands, B15 2TT, UK**UK
AUTHOR E-MAIL ADDRESS: j.gordan@bham.ac.uk
MEDIUM: print
ISSN: 0145-2126 _(ISSN print)
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

12/3/17  (Item 17 from file: 5)
DIALOG(R)File  5:Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

17781139  BIOSIS NO.: 200400147800
CD40 ligand (CD40L) stimulation prior to conventional cytogenetic analysis reveals a high frequency of complex karyotype aberrations in patients with CLL: A comparison with clinical and prognostic features of 92 patients.
AUTHOR: Mayr Christine (Reprint); Schoch Claudia (Reprint); Buhmann Raymund (Reprint); Wendtner Clemens (Reprint); Hallek Michael (Reprint)
AUTHOR ADDRESS: Department of Internal Medicine, Klinikum Grosshadern, Ludwig-Maximilians University, Munich, Germany**Germany
MEDIUM: print
CONFERENCE/MEETING: 45th Annual Meeting of the American Society of Hematology San Diego, CA, USA December 06-09, 2003; 20031206
SPONSOR: American Society of Hematology
Comparative efficacy of Rituximab and a fully human anti-CD40
antagonist antibody in vitro and in xenograft ***lymphoma*** models.

**AUTHOR:** Long Li (Reprint); Tong Xia (Reprint); Patawaran Montesa (Reprint);
Lugman Mohammad (Reprint)

**AUTHOR ADDRESS:** Research, Chiron Corporation, Emeryville, CA, USA**USA


**MEDIUM:** print

**CONFERENCE/MEETING:** 45th Annual Meeting of the American Society of
Hematology San Diego, CA, USA December 06-09, 2003; 20031206

**SPONSOR:** American Society of Hematology

**ISSN:** 0006-4971

**DOCUMENT TYPE:** Meeting; Meeting Poster; Meeting Abstract

**RECORD TYPE:** Abstract

**LANGUAGE:** English

---

Induction of an immunogenic and apoptotic phenotype in B chronic
lymphocytic leukemia (B-CLL) cells by immunostimulatory PyNTTTGT
oligodeoxynucleotides (ODN).

**AUTHOR:** Dupont Juan (Reprint); Flo Juan; Zorzopoulos Jorge; Riveros Dardo
(Reprint); Lopez Ricardo; Garay Guy (Reprint); Cacchione Roberto
(Reprint)

**AUTHOR ADDRESS:** Hematology, CEMIC, Buenos Aires, Argentina**Argentina

**JOURNAL:** Blood 102 (11): e429a-430a November 16, 2003 2003

**MEDIUM:** print

**CONFERENCE/MEETING:** 45th Annual Meeting of the American Society of
Hematology San Diego, CA, USA December 06-09, 2003; 20031206

**SPONSOR:** American Society of Hematology

**ISSN:** 0006-4971

**DOCUMENT TYPE:** Meeting; Meeting Poster; Meeting Abstract

**RECORD TYPE:** Abstract

**LANGUAGE:** English

---

Analysis of tumor-specific T cell immune response in follicular
non-Hodgkin's ***lymphoma*** patients treated with ***rituximab***.

**AUTHOR:** Weng Wen-Kai (Reprint); Levy Ronald (Reprint)

**AUTHOR ADDRESS:** Medicine/Oncology, Stanford University School of Medicine,
Stanford, CA, USA**USA

CD40 Ligation Induces Expression of Antigen Processing and Presentation Genes in Chronic Lymphocytic **Leukemia*** Cells.

AUTHOR: Kohlmann Alexander (Reprint); Dicker Frank (Reprint); Moritz Dirk R (Reprint); Maass Gerd (Reprint); Seeber Stefan (Reprint); Haferlach Torsten (Reprint); Kipps Thomas J (Reprint)

AUTHOR ADDRESS: Pharma Research, Roche Diagnostics GmbH, Penzberg, Germany **Germany


MEDIUM: print

CONFERENCE/MEETING: 44th Annual Meeting of the American Society of Hematology Philadelphia, PA, USA December 06-10, 2002; 20021206

SPONSOR: American Society of Hematology

ISSN: 0006-4971

DOCUMENT TYPE: Meeting; Meeting Poster; Meeting Abstract

RECORD TYPE: Abstract

LANGUAGE: English

Human anti-CD40 antagonistic antibodies inhibit the proliferation of human B cell non-Hodgkin's lymphoma

AUTHOR: Weng Wen-Kai (Reprint); Wang Changyu; Chu Keting; Levy Ronald (Reprint)

AUTHOR ADDRESS: Medicine/Oncology, Stanford University, Stanford, CA, USA** USA


MEDIUM: print

CONFERENCE/MEETING: 43rd Annual Meeting of the American Society of Hematology, Part 1 Orlando, Florida, USA December 07-11, 2001; 20011207

SPONSOR: American Society of Hematology

ISSN: 0006-4971

DOCUMENT TYPE: Meeting; Meeting Abstract

RECORD TYPE: Abstract

LANGUAGE: English

Generation of polyclonal plasma cells from peripheral blood B cells: How to
get a normal counterpart of malignant plasma cells

12/3/24 (Item 24 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

15977603 BIOSIS NO.: 200100149442
CpG DNA increases primary malignant B cell expression of costimulatory
molecules and target antigens
AUTHOR: Jahrsdorfer Bernd; Hartmann Gunther; Racila Emil; Jackson Wallen;
Muhlenhoff Lars; Meinhardt Gerold; Endres Stefan; Link Brian K; Krieg
Arthur M; Weiner George J (Reprint)
AUTHOR ADDRESS: University of Iowa Cancer Center, University of Iowa, 5970Z
JPP, Iowa City, IA, 52242, USA**USA
MEDIUM: print
ISSN: 0741-5400
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

12/3/25 (Item 25 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

15701561 BIOSIS NO.: 200000419874
A flow cytometric immune function assay for human peripheral blood
dendritic cells
AUTHOR: Willmann Kerstin (Reprint); Dunne John F
AUTHOR ADDRESS: 2350 Qume Drive, San Jose, CA, 95131, USA**USA
MEDIUM: print
ISSN: 0741-5400
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

12/3/26 (Item 26 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

15321415 BIOSIS NO.: 200000039728
Expression of CD40 and its ligand, CD40L, in intestinal lesions of Crohn's
disease
AUTHOR: Battaglia Edda; Biancone Luigi; Resegotti Andrea; Emanuelli Giorgio
; Fronda Gian Ruggero; Camussi Giovanni (Reprint)
Expression of CD40/CD40 ligand and Bcl-2 family proteins in labial salivary glands of patients with Sjogren's syndrome

AUTHOR: Nakamura Hideki; Kawakami Atushi; Tominaga Masahiro; Migit Kiyoshi; Kambai Yojiro; Nakamura Tatsufumi; Eguchi Katsumi (Reprint)

AUTHOR ADDRESS: The First Department of Internal Medicine, Nagasaki University School of Medicine, 1-7-1 Sakamoto, Nagasaki City, 852-8501, Japan

JOURNAL: Laboratory Investigation 79 (3): p261-269 March, 1999

Chronic lymphocytic leukemia B cells can express CD40 ligand and demonstrate T-cell type costimulatory capacity

AUTHOR: Schattner Elaine J (Reprint); Mascarenhas John; Reyfman Inna; Koshy Mary; Woo Caroline; Friedman Steven M; Crow Mary K

AUTHOR ADDRESS: Room C-640, Cornell Univ. Med. Coll., 1300 York Ave., New York, NY 10021, USA


Increased inhibition of proliferation of human B cell lymphomas following ligation of CD40, and either CD19, CD20, CD95 or surface immunoglobulin

AUTHOR: Benoit Nicole E; Wade William F (Reprint)

AUTHOR ADDRESS: Dep. Microbiol., Dartmouth Med. Sch., Lebanon, NH 03756, USA

12/3/30  (Item 30 from file: 5)
DIALOG(R) File  5: Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

13374833  BIOSIS NO.: 199699008893
CD20 and CD40 mediated mitogenic responses in B-lineage acute
lymphoblastic leukaemia
AUTHOR: Smiers Frans J; Van Paassen Marleen; Hahlen Karel; Lowenberg Bob;
Touw Ivo P (Reprint)
AUTHOR ADDRESS: Inst. Haematol., Erasmus Univ. Rotterdam, PO Box 1738, 3000
Dr Rotterdam, Netherlands**Netherlands
ISSN: 0007-1048
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

12/3/31  (Item 31 from file: 5)
DIALOG(R) File  5: Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

13000597  BIOSIS NO.: 199598468430
Antibodies to CD40 prevent Epstein-Barr virus-mediated human B-cell
lymphomagenesis in severe combined immune deficient mice given
human peripheral blood lymphocytes
AUTHOR: Murphy William J (Reprint); Funakoshi Satoshi; Beckwith Margaret;
Rushing Susan E; Conley Denise K; Armitage Richard J; Fanslow William C;
Rager Helen C; Taub Dennis D; Ruscetti Francis W; Longo Dan L
AUTHOR ADDRESS: Biol. Carcinogenesis and Dev. Program, Program Resources
Inc./DynCorp, NCI-FCRDC, Build. 567, Room 141, Frederick, MD 21702-1201,
USA**USA
ISSN: 0006-4971
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

12/3/32  (Item 32 from file: 5)
DIALOG(R) File  5: Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

12064964  BIOSIS NO.: 199497086249
Differential expression of surface antigens on activated endothelium
AUTHOR: Favaloro Emmanuel J
Westmead Hosp., Westmead, NSW 2145, Australia**Australia
ISSN: 0818-9641
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
Characterization of a cell surface glycoprotein IFO-3, expressed on activated human B and T lymphocytes

AUTHOR: Sidorenko Svetlana P; Clark Edward A

AUTHOR ADDRESS: Regional Primate Res. Cent. SJ-50, Univ. Washington, Seattle, WA 98195, USA**USA

JOURNAL: Journal of Immunology 151 (9): p4614-4624 1993 1993

ISSN: 0022-1767

DOCUMENT TYPE: Article; Literature Review

RECORD TYPE: Abstract

LANGUAGE: English

The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: Expression of a soluble form of gp39 with B cell co-stimulatory activity

AUTHOR: Hollenbaugh Diane (Reprint); Groismaire Laura S (Reprint); Kullas Christopher D (Reprint); Chalupy N Jan (Reprint); Braesch-Andersen Sten; Stamenkovic Randolph J Vv Noellea; Ledbetter Jeffrey A (Reprint); Aruffo Alejandro (Reprint)

AUTHOR ADDRESS: Bristol-Myers Squibb Pharmaceutical Research Inst., Seattle, Wash. 98121, USA**USA


ISSN: 0261-4189

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

IL-4 INDUCES CONFORMATIONAL CHANGE OF CD20 ANTIGEN VIA A PROTEIN KINASE C-INDEPENDENT PATHWAY ANTAGONISTIC EFFECT OF ANTI-CD40 MONOCLONAL ANTIBODY

AUTHOR: DANCESCU M (Reprint); WU C; RUBIO M; DELESPESSE G; SARFATI M

AUTHOR ADDRESS: ALLERGY RES LAB, NOTRE-DAME HOSP RES CENT, 1560 SHERBROOKE ST EAST, MONTREAL, QUE H2L 4M1**CANADA


ISSN: 0022-1767

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: ENGLISH
0082010530 EMBASE No: 2007444915
CD40 expression identifies a prognostically favourable subgroup of diffuse large B-cell lymphoma
Linderoth J.; Ehinger M.; Jerkeman M.; Bendahl P.-O.; Akerman M.;
Berglund M.; Enblad G.; Erlanson M.; Roos G.; Cavallin-Stahl E.
Department of Oncology, Institution of Clinical Sciences, Lund University
Hospital, Lund, Sweden
CORRESP. AUTHOR/AFFIL: Linderoth J.: Department of Oncology, Institution
of Clinical Sciences, Lund University Hospital, Lund, Sweden

Leukemia and Lymphoma ( Leuk. Lymphoma ) (United Kingdom) September 1,
2007, 48/9 (1774-1779)
CODEN: LELYE ISSN: 1042-8194 eISSN: 1029-2403
PUBLISHER ITEM IDENTIFIER: 781803128
DOI: 10.1080/10428190701494520
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 26

12/3/37 (Item 2 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0081529562 EMBASE No: 2006593143
Cancer: Novel therapeutic strategies that exploit the TNF-related
apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway
Cretney E.; Takeda K.; Smyth M.J.
Cancer Immunology Program, Trescowthick Research Laboratories, Peter
MacCallum Cancer Centre, East Melbourne, Vic. 3002, Australia
AUTHOR EMAIL: mark.smyth@petermac.org
CORRESP. AUTHOR/AFFIL: Smyth M.J.: Cancer Immunology Program,
Trescowthick Research Laboratories, Peter MacCallum Cancer Centre, East
Melbourne, Vic. 3002, Australia
CORRESP. AUTHOR EMAIL: mark.smyth@petermac.org

CODEN: IJBBF ISSN: 1357-2725
PUBLISHER ITEM IDENTIFIER: S1357272506002792
DOI: 10.1016/j.biocel.2006.10.005
DOCUMENT TYPE: Journal; Short Survey RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 44

12/3/38 (Item 3 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0081342922 EMBASE No: 2006405477
Can drug effects help elucidate the pathogenesis of SLE?
Fang C.J.; Hahn B.H.; Furst D.E.
UCLA Medical School, Rheumatology Division, 1000 Veteran Avenue, Los
Angeles, CA 98101, United States
AUTHOR EMAIL: defurst@mednet.ucla.edu
CORRESP. AUTHOR/AFFIL: Furst D.E.: UCLA Medical School, Rheumatology
Division, 1000 Veteran Avenue, Los Angeles, CA 98101, United States
CORRESP. AUTHOR EMAIL: defurst@mednet.ucla.edu
New treatments for SLE: Cell-depleting and anti-cytokine therapies
Anolik J.H.; Aringer M.
Allergy, Immunology and Rheumatology Unit, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, United States
AUTHOR EMAIL: jennifer; anolik@urmc.rochester.edu
CORRESP. AUTHOR/AFFIL: Anolik J.H.: Allergy, Immunology and Rheumatology Unit, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, United States
CORRESP. AUTHOR EMAIL: jennifer; anolik@urmc.rochester.edu

Fc receptor targeting in the treatment of allergy, autoimmune diseases and cancer
Nakamura A.; Akiyama K.; Takai T.
Tohoku University, Dept. of Experimental Immunology, Inst. of Development ageing/Cancer, Seiryo 4-1, Sendai 980-8575, Japan
AUTHOR EMAIL: aki@idac.tohoku.ac.jp
CORRESP. AUTHOR/AFFIL: Nakamura A.: Tohoku University, Dept. of Experimental Immunology, Inst. of Development ageing/Cancer, Seiryo 4-1, Sendai 980-8575, Japan
CORRESP. AUTHOR EMAIL: aki@idac.tohoku.ac.jp

Expert Opinion on Therapeutic Targets (Expert Opin. Ther. Targets) (United Kingdom) February 1, 2005, 9/1 (169-190)
CODEN: EGTTA ISSN: 1472-8222
DOI: 10.1517/14728222.9.1.169
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract LANGUAGE: English SUMMARY LANGUAGE: English
Selective depletion of activated T cells: The CD40L-specific antibody experience
Hargreaves R.E.G.; Monk N.J.; Jurcevic S.
Dept. of Nephrology and Transplant., Guy's, King's St. Thomas' Med. Sch.,
Guy's Hospital, London, SE1 9RT, United Kingdom
AUTHOR EMAIL: stipo.jurcevic@kcl.ac.uk
CORRESP. AUTHOR/AFFIL: Jurcevic S.: Dept. of Nephrology and Transplant.,
Guy'S, King'S St. Thomas' Med. Sch., Guy'S Hospital, London, SE1 9RT,
United Kingdom
CORRESP. AUTHOR EMAIL: stipo.jurcevic@kcl.ac.uk

Indolent B-cell malignancies: Immune recognition and antiself
Gribben J.G.
Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Avenue,
Boston, MA 02115, United States
AUTHOR EMAIL: john; gribben@dfci.harvard.edu
CORRESP. AUTHOR/AFFIL: Gribben J.G.: Dana Farber Cancer Institute,
Harvard Medical School, 44 Binney Avenue, Boston, MA 02115, United States
CORRESP. AUTHOR EMAIL: john; gribben@dfci.harvard.edu

16th Annual Scientific Meeting of the Society for Biological Therapy
Dillman R.O.; Dillman J.B.
Clin. and Laboratory Cancer Research, Hoag Cancer Center, Bldg 41, 1 Hoag
Drive, Newport Beach, CA 92658, United States
Expert Opinion on Biological Therapy (Expert Opin. Biol. Ther.) (United Kingdom) May 21, 2002, 2/2 (223-227)
CODEN: EOBTA ISSN: 1471-2598
DOI: 10.1517/14712598.2.2.223
DOCUMENT TYPE: Journal; Conference Paper RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English

12/3/44 (Item 9 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0078325759 EMBASE No: 2000375362

Immunotherapeutic strategies for the treatment of plasma cell malignancies
Treon S.P.; Raje N.; Anderson K.C.
Division of Hematologic Malignancies, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, United States
CORRESP. AUTHOR/AFFIL: Anderson K.C.: Division of Hematologic Malignancies, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, United States

Seminars in Oncology (Semin. Oncol.) (United States) November 13, 2000, 27/5 (598-613)
CODEN: SOLGA ISSN: 0093-7754
DOCUMENT TYPE: Journal; Conference Paper RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 156

12/3/45 (Item 10 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0078280176 EMBASE No: 2000329766

Differentiation of antigen-presenting cells (dendritic cells and macrophages) for therapeutic application in patients with lymphoma
Chaperot L.; Chokri M.; Jacob M.-C.; Drillat P.; Garban F.; Egelhofer H.; Molens J.-P.; Sotto J.-J.; Bensa J.-C.; Plumas J.
Department of Cell Therapy, ETS de l'Isere et de la Savoie, BP 35, F-38701 La Tronche Cedex, France
CORRESP. AUTHOR/AFFIL: Chaperot L.: Department of Cell Therapy, ETS de l'Isere et de la Savoie, BP 35, F-38701 La Tronche Cedex, France

Leukemia (Leukemia) (United Kingdom) October 2, 2000, 14/9 (1667-1677)
CODEN: LEUKE ISSN: 0887-6924
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 49

12/3/46 (Item 11 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0076676499 EMBASE No: 1996352908
Increased inhibition of proliferation of human B cell lymphomas following ligation of CD40, and either CD19, CD20, CD95 or surface immunoglobulin

Benoit N.E.; Wade W.F.
Department of Microbiology, Dartmouth Medical School, Lebanon, NH 03756, United States
AUTHOR EMAIL: william.wade@dartmouth.edu
CORRESP. AUTHOR/AFFIL: Wade W.F.: Department of Microbiology, Dartmouth Medical School, Lebanon, NH 03756, United States

Immunopharmacology ( IMMUNOPHARMACOLOGY ) (Netherlands) November 1, 1996, 35/2 (129-139)
CODEN: IMMUD ISSN: 0162-3109
PUBLISHER ITEM IDENTIFIER: S0162310996001385
DOI: 10.1016/S0162-3109(96)00138-5
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 33

12/3/47 (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2008 Dialog. All rts. reserv.

16916665 PMID: 16525683
Optimal combination chemotherapy and chemoradiotherapy with etoposide for advanced cervical squamous ***cancer*** cells in vitro.
Tanaka Tetsuji; Bai Tao; Yukawa Kazunori; Umesaki Naohiko
Department of Obstetrics and Gynecology, Wakayama Medical University,
Wakayama 641-0012, Japan. tetanaka@wakayama-med.ac.jp
Oncology reports (Greece) Apr 2006, 15 (4) p939-47, ISSN 1021-335X
--Print Journal Code: 9422756
Publishing Model Print
Document type: Journal Article; Research Support, Non-U.S. Gov't
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed

12/3/48 (Item 2 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2008 Dialog. All rts. reserv.

14671788 PMID: 12072193
CM1 ligation initiates apoptosis in a caspase 8-dependent manner in Ramos cells and in a mitochondria-controlled manner in Raji cells.
Kim Daejin; Hur Dae Young; Kim Yeong Seok; Lee Kyungmi; Lee Youngseon; Cho Daeho; Kang Jae Seung; Kim Young-in; Hahm Bunsil; Yang Youlhee; Yoon Suyoung; Kim Seonghan; Lee Won Bok; Park Hae Young; Kim Yoon Bern; Hwang Young-il; Chang Ka Y; Lee Wang Jae
Department of Anatomy, Seoul National University, College of Medicine and Institute of Allergy and Clinical Immunology, Medical Research Center,
Seoul National University, Seoul, South Korea.
Human immunology (United States) Jul 2002, 63 (7) p576-87, ISSN 0198-8859--Print Journal Code: 8010936
Publishing Model Print
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed
12/3/49  (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2008 American Chemical Society. All rts. reserv.

148512812  CA: 148(23)512812w  PATENT
Base-modified RNA for increasing protein expression
INVENTOR(AUTHOR): Hoerr, Ingmar; Von der Muelbe, Florian
LOCATION: Germany,
ASSIGNEE: Curevac G.m.b.H.
PATENT: PCT International ; WO 200852770 A2  DATE: 20080508
PAGES: 105pp.  CODEN: PXIXD2  LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: A61K-000/A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BH; BR; BW;
BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DO; DZ; EC; EE; EG; ES; FI;
GB; GD; GE; GH; GM; GT; HM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP;
KR; KZ; LA; LC; LJ; LR; LS; LT; LU; LY; MA; MD; ME; MG; NK; MN; MW; MX; MY;
MZ; NA; NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG; SK;
SL; SM; SV; SY; TJ; TM; TN; TR; TT; TZ; DESIGNATED REGIONAL: AT; BE; BG; CH;
CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC;
MT; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW;
ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG;
ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

12/3/50  (Item 2 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2008 American Chemical Society. All rts. reserv.

147110188  CA: 147(6)110188d  PATENT
Use of stimulatory anti-CD40 antibodies in the treatment of diseases
associated with aberrant CD40 presentation on cell surfaces
INVENTOR(AUTHOR): Drachman, Jonathan; Law, Che-Leung; Lewis, Tim
LOCATION: USA
ASSIGNEE: Seattle Genetics, Inc.
PATENT: PCT International ; WO 200675326 A2  DATE: 20070705
2006PV811353 (20060605) *US 2006PV811301 (20060605) *US 2006PV847234
(20060925)
PAGES: 125pp.  CODEN: PXIXD2  LANGUAGE: English
PATENT CLASSIFICATIONS:
IPCR/8 + Level Value Position Status Version Action Source Office:
A61K-0039/395  A I F B 20060101
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY;
BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD;
GE; GH; GM; GT; HM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR; KZ;
LA; LC; LS; LT; LU; LV; LY; MA; MD; MG; MK; MN; MW; MX; MY; MZ; NA;
NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG; SK; SL; SM;
SV; SY; TJ; TM; TN; TR; TT; TZ; UA; UG DESIGNATED REGIONAL: AT; BE; BG; CH;
CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC;
NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML;
MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM;
ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

12/3/51  (Item 3 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2008 American Chemical Society. All rts. reserv.
144231465 CA: 144(13)231465p PATENT
Humanized antibodies with Man3GlcNAc2 modification to increase
FcγRIII receptor binding and ADCC for therapeutic use
INVENTOR(AUTHOR): Gerngross, Tillman U.; Li, Huijuan; Wildt, Stefan
LOCATION: USA
(20040721) *US 2005500240 (20050323)
PAGES: 47 pp., Cont.-in-part of U.S. Ser. No. 500,240. CODEN: USXXCO
LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: 424130100
IPCR/8 + Level Value Position Status Version Action Source Office:
C07K-0016/28 A I F B 20060101 20060216 H US
C07H-0021/04 A I L B 20060101 20060216 H US
C12P-0021/06 A I L B 20060101 20060216 H US
A61K-0039/395 A I L B 20060101 20060216 H US
C12N-0005/06 A I L B 20060101 20060216 H US
12/3/52 (Item 4 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2008 American Chemical Society. All rts. reserv.

144005405 CA: 144(1)5405n PATENT
Antibody glycosylation variants having increased antibody-dependent
cellular cytotoxicity
INVENTOR(AUTHOR): Umana, Pablo; Jean-Mairet, Joel; Bailey, James E.
LOCATION: Switz.
ASSIGNEE: Glycart Biotechnology AG
APPLICATION: US 2005199232 (20050809) *US 2002211554 (20020805) *US
2003633697 (20030805)
PAGES: 28 pp., Cont.-in-part of U.S. Ser. No. 633,697. CODEN: USXXCO
LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: 435069100; C07K-016/28A; C07H-021/04B; C12P-021/06B;
C12N-0005/06B
12/3/53 (Item 5 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2008 American Chemical Society. All rts. reserv.

143241996 CA: 143(14)241996f PATENT
Methods using a toll-like receptor-2 (TLR2) agonist for treating
immunopathological disorders
INVENTOR(AUTHOR): Raz, Eyal; Redecke, Vanessa Doreen; Horner, Anthony A.
LOCATION: USA
ASSIGNEE: The Regents of the University of California
PATENT: PCT International ; WO 200579419 A2 DATE: 20050901
PAGES: 50 pp. CODEN: P1XXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: A61K-000/A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY;
BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD;
GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LL; LR; LS;
LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL;
PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US;
12/3/54  (Item 6 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2008 American Chemical Society. All rts. reserv.
143053027 CA: 143(4)53027s JOURNAL
B-Cell Lymphomas Differ in their Responsiveness to CpG
Oligodeoxynucleotides
AUTHOR(S): Jahrs dorfer, Bernd; Mueh lenhoff, Lars; Blackwell, Sue E.;
Wagner, Moritz; Poeck, Hendrik; Hartmann, Evelyn; Jox, Ralf; Giese, Thomas;
Emmerich, Bertold; Endres, Stefan; Weiner, George J.; Hartmann, Gunther
LOCATION: Division of Clinical Pharmacology, University of Munich, Munich,
Germany,
VOLUME: 11 NUMBER: 4 PAGES: 1490-1499 CODEN: CCREF4 ISSN: 1078-0432
LANGUAGE: English PUBLISHER: American Association for Cancer Research

12/3/55  (Item 7 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2008 American Chemical Society. All rts. reserv.
142273998 CA: 142(15)273998d PATENT
Treatment for CD5+ B cell lymphoma
INVENTOR(AUTHOR): Miller, Richard L.; Spaner, David E.
LOCATION: USA
ASSIGNEE: 3M Innovative Properties Company
2004PV561440 (20040412)
PAGES: 25 pp. CODEN: USXXCO LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: 514292000; A61K-031/4745A

12/3/56  (Item 8 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2008 American Chemical Society. All rts. reserv.
141172878 CA: 141(11)172878p PATENT
Engineering of glycosylation profile of antibody Fc region to increase Fc
receptor binding affinity and effector function for treating cancer
INVENTOR(AUTHOR): Umana, Pablo; Bruenker, Peter; Ferrara, Claudia; Suter,
Tobias
LOCATION: Switz.
ASSIGNEE: Glycart Biotechnology Ag
PATENT: PCT International ; WO 200465540 A2 DATE: 20040805
APPLICATION: WO 20041B844 (2004122) *US PV441307 (20030122) *US PV491254
(20030731) *US PV495142 (20030815)
PAGES: 231 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: C12N-000/A
DESIGNATED COUNTRIES: AE; AE; AG; AL; AL; AM; AM; AM; AT; AT; AU; A2; A2;
BA; BB; BG; BR; BR; BW; BY; BY; BZ; BZ; CA; CH; CN; CN; CO; CO; CR; CR;
CU; CU; CZ; CZ; DE; DE; DK; DK; DM; DZ; EC; EC; EE; EE; EG; ES; ES; FI; FI;
138152272 CA: 138(11)152272w PATENT
Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
INVENTOR(AUTHOR): Jean-Mairet, Joel; Umana, Pablo; Bailey, James E.
LOCATION: Switz.
ASSIGNEE: Glycart Biotechnology AG; Bailey, Sean
PATENT: PCT International ; WO 200311878 A2 DATE: 200303213
PAGES: 68 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: C07H-000/A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;
CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH;
GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU;
LV; MA; MD; MG; MN; MW; MX; MZ; NO; NZ; OM; PH; PL; PT; RO; RU; SD; SE;
SG; SI; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UG; UZ; VN; YU; ZA; ZM; ZW; AM;
AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ;
SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI;
FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; SK; TR; BF; BJ; CF; CG; CI; CM; GA;
GN; GQ; GW; ML; MR; NE; SN; TD; TG;
? t 12/7/78,30,42,44,45

14434691 BIOSIS NO.: 199800228938
Chronic lymphocytic leukemia B cells can express CD40 ligand and demonstrate T-cell type costimulatory capacity
AUTHOR: Schattner Elaine J (Reprint); Mascarenhas John; Reyfman Inna; Koshy
Mary; Woo Caroline; Friedman Steven M; Crow Mary K
AUTHOR ADDRESS: Room C-640, Cornell Univ. Med. Coll., 1300 York Ave., New
York, NY 10021, USA**USA
MEDIUM: print
ISSN: 0006-4971
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: Chronic lymphocytic leukemia (CLL) is characterized by a clonal expansion of CD5+ B cells in the peripheral blood. Associated immune aberrations include abnormal Th-cell function and pathogenic autoantibodies. Under most circumstances, CLL B cells do not proliferate in culture and express a limited repertoire of surface antigens, including CD19, CD20**, CD23, CD27, CD40, and CD70. In this report, we demonstrate that freshly isolated B cells from a subset of CLL cases constitutively express CD40 ligand (CD40L, CD154), a member of the tumor necrosis factor family which is normally expressed by activated CD4+ T cells and mediates T-cell-dependent B-cell proliferation and antibody production. The degree of CD40L expression varied considerably among the CLL cases examined. CD40L was detected in purified
CLL B cells by immunofluorescence flow cytometry, by RT-PCR, and by immunoprecipitation. To demonstrate that **CD40L** in the CLL B cells is functional, we used irradiated CLL cells to stimulate IgG production by target, nonmalignant B cells in coculture. The CLL B cells induced IgG production by normal B cells to a similar degree as did purified T cells in a process which was partially inhibited by monoclonal antibody to CD40L. This is one of the first reports of CD40L expression in a B-cell **tumor**. The data suggest that CD40L in the **tumor** cells may be a factor in the generation of pathologic antibodies by normal B cells in some patients with CLL.

12/7/30  (Item 30 from file: 5)
DIALOG(R)File  5:Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

13374833  BIOSIS NO.: 199699008893
CD20 and CD40 mediated mitogenic responses in B-lineage acute lymphoblastic leukaemia

AUTHOR: Smiers Frans J; Van Paassen Marleen; Hahlen Karei; Lowenberg Bob; Touw Ivo P (Reprint)

AUTHOR ADDRESS: Inst. Haematol., Erasmus Univ. Rotterdam, PO Box 1738, 3000
Dr Rotterdam, Netherlands**Netherlands

ISSN: 0007-1048
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: Activation of CD20, a cross-membrane ion channel, induces cell cycle progression from G-0 to G-1 in B lymphocytes. Subsequent activation of CD40, a membrane receptor of the nerve growth factor receptor superfamily, transits the B cells to the S phase. CD40 may also act synergistically in combination with IL-4 (B lymphocytes) or IL-3/IL-7 (B-cell precursors). We investigated the proliferative responses of B-lineage acute lymphoblastic leukaemia (ALL) cells to CD20/ **CD40** activation. In 18/56 ALL cases, **CD20** activation resulted in significant **increases** in DNA synthesis. Similar, although more moderate, effects were seen of activation of **CD40** in 10/44 cases. Responses to CD20 or CD40 activation were independent of co-stimulation with IL-3, IL-4 or IL-7, and various cocktails of the different growth stimuli did not act synergistically.

12/7/42  (Item 7 from file: 73)
DIALOG(R)File  73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0079891356  EMBASE No: 2004076254
Indolent B-cell malignancies: Immune recognition and antiself
Gribben J.G.
Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Avenue, Boston, MA 02115, United States
AUTHOR EMAIL: john; gribben@dfci.harvard.edu
CORRESP. AUTHOR/AFFIL: Gribben J.G.: Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Avenue, Boston, MA 02115, United States
CORRESP. AUTHOR EMAIL: john; gribben@dfci.harvard.edu

Leukemia and Lymphoma ( Leuk. Lymphoma ) (United Kingdom) December 1, 2003, 44/SUPPL. 3 (S77-S83)
CODEN: LELYE  ISSN: 1042-8194
B-cell malignancies appear to be ideal candidates for treatment with immunotherapeutic approaches. Monoclonal antibodies that target cell-surface determinants have been used as single agents in B-cell malignancies, in combination with chemotherapy, and coupled to other agents to create radioimmunoconjugates and immunotoxins. Another approach is to take advantage of the graft-vs.-lymphoma effect seen following allogeneic bone marrow transplantation. To exploit this effect without inducing the complication of graft-vs.-host disease, it is necessary to understand the mechanisms whereby lymphoma cells escape T-cell-mediated responses. ***CD40*** activation may offer a means of increasing the immunogenicity of lymphoma cells and of stimulating allogeneic T-cell proliferation and cytokine production. Vaccination using tumor-specific antigens shows promise as a therapeutic strategy. Pre-clinical studies with immunoglobulin idioype peptides have shown that humoral and cellular immune responses can be stimulated by antibodies to these peptides, but better tumor antigens need to be identified that can reliably generate cytotoxic T-cell responses. Candidate antigens include heteroclitic peptides from the immunoglobulin V region and newly identified antigens including the cytochrome P450 1B1. Clinical trials are ongoing in all these fields.
(mAb) Rituximab (Genentech, South San Francisco, CA) in patients with WM and certain patients with MM. The use of agents to induce MM- and WM-selective antigens for targeting in serotherapy has been proposed based on studies demonstrating the upregulation of CD20 by interferon-gamma (IFN-gamma), and of MUC1 core protein by dexamethasone (DEX) on malignant plasma cells. Strategies to induce allogeneic anti-MM immunity have included immunization of the marrow donor to idiotypic protein, as well as DLI. In addition, proposed immunization strategies aimed at inducing autologous immunity include vaccination with dendritic cells pulsed with MM antigens, MM cell-dendritic cell fusions, carrier-linked idiootype protein, catalytic subunit of telomerase, or DNA encoding for single-chain variable fragments (scFv) linked to a carrier protein gene. Whole ***tumor*** vaccination strategies are also being examined and include the use of MM cells transfected and/or stimulated with cytokines, costimulatory molecules, or ***CD40*** ligand. Finally, potential obstacles to the use of immunotherapy, including the presence of resistance antigens on MM and WM ***tumor*** cells, are discussed. Copyright (C) 2000 by W.B. Saunders Company.

12/7/45 (Item 10 from file: 73)
DIALOG(R) File 73:EMBASE
(c) 2008 Elsevier B.V. All rights reserved.

0078280176 EMBASE No: 2000329766

Differentiation of antigen-presenting cells (dendritic cells and macrophages) for therapeutic application in patients with lymphoma
Chaperot L.; Chokri M.; Jacob M.-C.; Drillat P.; Garban F.; Egelhofer H.; Molens J.-P.; Sotto J.-J.; Bensa J.-C.; Plumas J. 
Department of Cell Therapy, ETS de l'Isere et de la Savoie, BP 35, F-38701 La Tronche Cedex, France
CORRESP. AUTHOR/AFFIL: Chaperot L.: Department of Cell Therapy, ETS de l'Isere et de la Savoie, BP 35, F-38701 La Tronche Cedex, France

Leukemia (Leukemia) (United Kingdom) October 2, 2000, 14/9 (1667-1677)
CODEN: LEUKE ISSN: 0887-6924
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 49

The recent clinical trial in lymphoma using tumor antigen-loaded DCs (Hsu et al, Nature Med 1996; 2: 52) demonstrates the efficiency of the use of professional antigen presenting cells (APCs) for taking up, processing and presenting tumor protein in a vaccine strategy in ***cancer***. However, the production of large quantities of clinical grade APCs remains to be resolved. Here, we describe that both dendritic cells (DCs) and macrophages (M(empty set)s) can be efficiently differentiated in large numbers from lymphoma patients in spite of their disease and previous therapy. These cells were produced using the VAC and MAK cell processors according to standard operating procedures. DCs and M(empty set)s were differentiated from circulating monocytes in gas permeable hydrophobic bags, with 2% autologous serum and in the presence of GM-CSF and IL-13 or GM-CSF alone, respectively. DCs and M(empty set)s were then purified by counter flow centrifugation. Phenotypic, morphological and functional analysis showed that cells differentiated from patients with lymphoma present quite similar features to DCs and M(empty set)s produced from monocytes of healthy donors. Moreover, we show that M(empty set)s, when combined with CD20 antibody (Rituximab), can efficiently engulf tumor cells and propose that a such combination could be used for initiating a clinical trial in ***lymphoma***. Thus, the possibility of producing functional DC and M(empty set)s in large amounts...
in conditions compatible with therapeutic application will allow the
development of new immune strategies to eradicate lymphoma.

Set Items Description
S1 15 (CD40) (10N) (AGONIST?) AND (CD20 OR RITUXAN OR RITUXIMAB)
S2  9 RD S1 (unique items)
S3 434 (CD40) (10N) (ANTIBOD? OR IMMUNOGLOBULIN?) AND (CD20 OR RITUXAN OR RITUXIMAB)
S4 280 S3 AND (CANCER? OR TUMOR? OR NEOPLAS? OR TUMOUR? OR LEUKEMIA? OR LYMPHOMA?)
S5 241 RD S4 (unique items)
S6 24 S5 AND (CD40) (20N) (AGONIST? OR STIMULAT? OR INCREASE?)
S7 24 RD S6 (unique items)
S8  0 S (CD40?) (20N) (AGONIST? OR STIMULAT? OR INCREASE?) AND (CD20 OR RITUXAN OR RITUXIMAB)
S9 193 (CD40?) (20N) (AGONIST? OR STIMULAT? OR INCREASE?) AND (CD20 OR RITUXAN OR RITUXIMAB)
S10 105 RD S9 (unique items)
S12 57 RD S11 (unique items)
? s ss2c6 and cd40
  0 SS2C6
  34908 CD40
S13  0 SS2C6 AND CD40
? s s2c6 and cd40
  31 S2C6
  34908 CD40
S14 17 S2C6 AND CD40
? rd s14
S15  9 RD S14 (unique items)
? t s15/3/all

15/3/1 (Item 1 from file: 5)
DIALOG(R)File 5: Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

18838451 BIOSIS NO.: 200600183846
The humanized anti-Cd40 monoclonal antibody SGN-40 targets Hodgkin's
disease cells through multiple mechanisms.
AUTHOR: Law Che-Leung (Reprint); McEarchern Julie A; Cerveny Charles G;
Smith Leia M; Nesterova Albina; Gordon Kristine A; Grewal Iqbal S; Wahl
Alan F
AUTHOR ADDRESS: Seattle Genet Inc, Preclin Therapeut, Bothell, WA USA**USA
CONFERENCE/MEETING: 47th Annual Meeting of the
American-Society-of-Hematology Atlanta, GA, USA December 10-13, 2005;
20051210
SPONSOR: Amer Soc Hematol
ISSN: 0006-4971
DOCUMENT TYPE: Meeting; Meeting Abstract
RECORD TYPE: Abstract
LANGUAGE: English

15/3/2 (Item 2 from file: 5)
DIALOG(R)File 5: Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

13260372 BIOSIS NO.: 199698728205
CD40 antibodies defining distinct epitopes display qualitative differences in their induction of B-cell differentiation

AUTHOR: Bjorck P; Paulie S (Reprint)
AUTHOR ADDRESS: Dep. Immunology, Stockholm Univ., S-106 91 Stockholm, Sweden

ISSN: 0019-2805
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

15/3/3 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

12538024 BIOSIS NO.: 199598005857
Antibodies to distinct epitopes on the CD40 molecule co-operate in stimulation and can be used for the detection of soluble CD40

AUTHOR: Bjorck P (Reprint); Braesch-Andersen S; Paulie S

JOURNAL: Immunology 83 (3): p430-437 1994
ISSN: 0019-2805
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

15/3/4 (Item 4 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

11899684 BIOSIS NO.: 199396064100
CD40 plays an essential role in the activation of human B cells by murine EL4B5 cells

AUTHOR: Kweekeboom J (Reprint); De Boer M; Tager J M; De Groot C

ISSN: 0019-2805
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

15/3/5 (Item 5 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

11394539 BIOSIS NO.: 199294096380
AGONISTIC PROPERTIES OF ANTI-B CELL ANTIBODIES PURIFIED ON STAPHYLOCOCCAL PROTEIN A MAY BE DUE TO CONTAMINATING PROTEIN A

AUTHOR: Jakobson E (Reprint); Axelsson B; Paulie S

ISSN: 0022-1759
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: ENGLISH
The human B lymphocyte and carcinoma antigen, CDw40, is a phosphoprotein involved in growth signal transduction.

Paulie S; Rosen A; Ehlin-Henriksson B; Braesch-Andersen S; Jakobson E; Koho H; Perlmann P
Department of Immunology, University of Stockholm, Sweden.
Publishing Model Print
Document type: Journal Article; Research Support, Non-U.S. Gov't
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed

Combination therapy containing agents for deleting cells expressing CD40 and CD20 antigens
INVENTOR(AUTHOR): Grewal, Iqbal
LOCATION: USA
ASSIGNEE: Genentech, Inc.
APPLICATION: US 200299818 (20020314) *US 2001PV280805 (20010402)
PAGES: 22 pp. CODEN: USXXCO LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: 424144100; A61K-039/395A

Conjugates of dolastatin analogs with tumor antigen-binding antibodies for use in tumor therapy
INVENTOR(AUTHOR): Doronina, Svetlana O.; Senter, Peter D.; Toki, Brian E.; Ebens, Allen J.; Kline, Toni Beth; Polakis, Paul; Sliwkowski, Mark X.; Spencer, Susan D.
LOCATION: USA
ASSIGNEE: Seattle Genetics, Inc.
PATENT: PCT International ; WO 200581711 A2 DATE: 20050909
PAGES: 426 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: A61K-000/A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US;
UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LU; MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

15/3/9 (Item 3 from file: 399)
DIALOG(R) File 399: CA SEARCH (R)
(c) 2008 American Chemical Society. All rts. reserv.

134041105 CA: 134(4)11105s PATENT
Recombinant anti-CD40 antibody and uses thereof
INVENTOR(AUTHOR): Siegal, Clay B.; Wahl, Alan F.; Francisco, Joseph A.; Fell, Henry P., Jr
LOCATION: USA
ASSIGNEE: Seattle Genetics, Inc.; Fell, Henry P. Jr.
PATENT: PCT International; WO 200075348 A1 DATE: 20001214
APPLICATION: WO 20000515749 (20000608) *US 328296 (19990608)
PAGES: 91 pp. CODEN: PIQX0D LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: C12N-015/63A; C12N-015/00B; G01N-033/53B; A61K-038/00B;
C07K-005/00B; C07K-014/00B; C07K-016/00B; C07H-021/04B
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA;
CH; CN; CR; CU; CZ; DE; DK; DM; DZ; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU;
ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LG; LR; LS; LT; LU; LV; MA; MD;
MG; MK; MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM;
TR; TT; T2; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM
DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZW; AT;
BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF;
BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG
s sgn? and cd40
1838 sgn?
34908 CD40
s16 67 sgn? and cd40
rd s16
45 rd s16 (unique items)
s s17 and (antibod? or immunoglobulin)(20n)(sgn?)
45 s17
2338190 ANTIBOD?
694942 IMMUNOGLOBULIN
1838 sgn?
168 (ANTIBOD? OR IMMUNOGLOBULIN)(20N)(SGN?)
s18 30 s17 and (ANTIBOD? OR IMMUNOGLOBULIN)(20N)(SGN?)
t s18/3/1

18/3/1 (Item 1 from file: 5)
DIALOG(R) File 5: Biosis Previews (R)
(c) 2008 The Thomson Corporation. All rts. reserv.

0020170675 BIOSIS NO.: 200800217614
The humanized anti-CD40 monoclonal antibody, SGN-40, potentiated chemotherapy regimens in NHL xenograft models via pro-apoptotic signaling
AUTHOR: Lewis Timothy S (Reprint); McCormick Renee S; Kissler Kim; Stone Ivan J; Jonas Mechtild; Sutherland May S K; Gerber Hans-Peter; Drachman Jonathan G; Grewal Iqbal S; Law Che-Leung
AUTHOR ADDRESS: Seattle Genet Inc, Bothell, WA USA**USA
CONFERENCE/METING: 49th Annual Meeting of the American-Society-of-Hematology Atlanta, GA, USA December 08 -11, 2007;
New agents in development for non-Hodgkin's lymphoma

Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma

Results of a phase I trial of SGN-40 (anti-huCD40 mAb) in patients with relapsed multiple myeloma.
The humanized Anti-CD40 antibody SGN-40 inhibits tumor growth in LAG kappa-1A, a CD40(+) mouse model of human multiple myeloma.

AUTHOR: Campbell Richard A (Reprint); Gordon Melinda S; Sanchez Eric; Chen Haiming; Turker Lauren; Trac Olivia; Li Mingjie; Pang Shen; Bonavida Benjamin; Said Jonathan; Drachman Jonathan G; Berenson James R

AUTHOR ADDRESS: Inst Myeloma and Bone Canc Res, West Hollywood, CA USA**USA


CONFERENCE/MEETING: 48th Annual Meeting of the American-Society-of-Hematology Orlando, FL, USA December 09 -12, 2006; 20061209

SPONSOR: Amer Soc Hematol

ISSN: 0006-4971

DOCUMENT TYPE: Meeting; Meeting Poster

RECORD TYPE: Abstract

LANGUAGE: English

The humanized Anti-CD40 antibody, SGN-40, promotes apoptosis signaling and is effective in combination with standard therapies in lymphoma xenograft models.

AUTHOR: Lewis Timothy S (Reprint); Sutherland May S K; Jonas Mechthild; Cerveny Charles G; McCormick Renee; Wahl Alan F; Drachman Jonathan G; Grewal Iqbal S; Law Che-Leung

AUTHOR ADDRESS: Seattle Genet Inc, Bothell, WA USA**USA


CONFERENCE/MEETING: 48th Annual Meeting of the American-Society-of-Hematology Orlando, FL, USA December 09 -12, 2006; 20061209

SPONSOR: Amer Soc Hematol

ISSN: 0006-4971

DOCUMENT TYPE: Meeting; Meeting Poster

RECORD TYPE: Abstract

LANGUAGE: English


AUTHOR: Advani Ranjana (Reprint); Porrero-Torres Andres; Furman Richard R; Rosenblatt Joseph D; Younes Anas; Shankles Brooks; Harrop Kate; Drachman Jonathan G
Preclinical pharmacokinetics, pharmacodynamics and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates (vol 148, pg 1116, 2006)

AUTHOR: Kelley S K; Geizleichter T; Xie D; Lee W P; Darbonne W C; Qureshi F; Kessler K; Ofloazoglu E; Grewal I S


Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates

AUTHOR: Kelley Sean K; Geizleichter Thomas; Xie Dong; Lee Wyne P; Darbonne Walter C; Qureshi Ferhan; Kessler Kim; Ofloazoglu Ezogelin; Grewal Iqbal S (Reprint)

AUTHOR ADDRESS: Seattle Genet Inc, Dept Preclin Therapeut, 21823,30th Dr SE, Bothell, WA 98021 USA**USA

AUTHOR E-MAIL ADDRESS: igrewal@seagen.com


Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40 (vol 65, pg 8331, 2005)

AUTHOR: Law C-L; Gordon K A; Collier J; Klussman K; McEarchern J A; Cerveny C G; Mikan B J; Lee W P; Lin Z; Valdez P; Wahl A F; Grewal I S

Humanized anti CD-40 antibody SGN-40 effectively induces cytotoxicity against chronic lymphocytic leukemia (CLL) cells through antibody mediated cytotoxicity and demonstrates modest biologic evidence of CD40 activation

AUTHOR: Gowda Aruna C (Reprint); Zhao Xiaobin B; Cheney Carolyn; Mehter Najma; Lozanski Gerard; Lin Thomas S; Guster Sara; Drachman J G; Muthusamy Natarajan; Byrd John C

AUTHOR ADDRESS: Ohio State Univ, Columbus, OH 43210 USA**USA


SPONSOR: Amer Soc Hematol

ISSN: 0006-4971

DOCUMENT TYPE: Meeting; Meeting Poster

LANGUAGE: Abstract

---

A phase I humanized Anti-CD40 monoclonal antibody (SGN-40) in patients with multiple myeloma.

AUTHOR: Hussein Mohamad A (Reprint); Berenson James R; Niesvizky Ruben; Munshi Nikhil C; Harrop Kate L; McDonald Michael; Drachman Jonathan G

AUTHOR ADDRESS: Cleveland Clin Taussig Canc Ctr, Cleveland Clin Multiple Myeloma Res Program, Cleveland, OH USA**USA


SPONSOR: Amer Soc Hematol

ISSN: 0006-4971

DOCUMENT TYPE: Meeting; Meeting Poster

LANGUAGE: Abstract

---


AUTHOR: Advani Ranjana H (Reprint); Furman Richard R; Rosenblatt Joseph D; Younes Anas; Forero-Torres Andres; Harrop Kate L; Baumgartner Karen T;
The humanized anti-CD40 monoclonal antibody SGN-40
targets Hodgkin's disease cells through multiple mechanisms.

AUTHOR: Law Che-Leung (Reprint); McEarchern Julie A; Cerveny Charles G;
Smith Leia M; Nesterova Albina; Gordon Kristine A; Grewal Iqbal S; Wahl
Alan F

AUTHOR ADDRESS: Seattle Genet Inc, Preclin Therapeutic, Bothell, WA USA**USA

Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-
CD40 SGN-40-induced cytotoxicity in human multiple myeloma:
Clinical implications

AUTHOR: Tai Yu-Tzu; Li Xian-Feng; Catley Laurence; Coffey Rory; Breitkreutz
Iris; Bae Jooeun; Song WeiHua; Podar Klaus; Hideshima Teru; Chauhan
Dharminder; Schlossman Robert; Richardson Paul; Treon Steven P; Grewal
Iqbal S; Munshi Nikhil C; Anderson Kenneth C (Reprint)

AUTHOR E-MAIL ADDRESS: kennethanderson@dfci.harvard.edu
Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40

AUTHOR: Law Che-Leung (Reprint); Gordon Kristine A; Collier John; Klussmann Kerry; McEarchern Julie A; Cerveny Charles G; Mixan Bruce J; Lee Wyne P; Lin Zhonghua; Valdez Patricia; Wahl Alan P; Grewal Iqbal S

AUTHOR ADDRESS: Seattle Genet Inc, 21823 30th Dr SE, Bothell, WA 98021 USA

AUTHOR E-MAIL ADDRESS: claw@seagen.com


ISSN: 0008-5472

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

A phase I, multi-dose, dose escalation study of SGN-40 (anti-huCD40 mAb) in patients with refractory or recurrent multiple myeloma

AUTHOR: Hussein Mohamad A (Reprint); Niesvizky Ruben; Munshi Nikhil; Berenson James C; Anderson Kenneth C; Ryan Kate; Baumgartner Karen; Miller Dennis M; McDonald Michael

AUTHOR ADDRESS: Cleveland Clin Multiple Myeloma Res Progam, Taussig Canc Ctr, Cleveland, OH USA**USA


CONFERENCE/MEETING: 46th Annual Meeting of the American-Society-of-Hematology San Diego, CA, USA December 04 -07, 2004; 20041204

SPONSOR: Amer Soc Hematol

ISSN: 0006-4971

DOCUMENT TYPE: Meeting; Meeting Poster

RECORD TYPE: Abstract

Enhanced cytotoxicity of monoclonal antibody SGN-40 and immunomodulatory drug IMiD3 against human multiple myeloma

AUTHOR: Tai Yu-Tzu (Reprint); Catley Laurence; Li Xian-Feng; Hamasaki Makoto; Podar Klaus; Hideshima Teru; Chauhan Dharminder; Schlossman Robert; Richardson Paul; Streon Steven P; Munshi Nikhil C; Anderson Kenneth C

AUTHOR ADDRESS: Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Dept Med Oncol, Boston, MA 02115 USA**USA


CONFERENCE/MEETING: 46th Annual Meeting of the American-Society-of-Hematology San Diego, CA, USA December 04 -07, 2004; 20041204

SPONSOR: Amer Soc Hematol

ISSN: 0006-4971

DOCUMENT TYPE: Meeting; Meeting Poster

RECORD TYPE: Abstract
17933452  BIOSIS NO.: 200400304209
Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells:
Clinical implications
AUTHOR: Tai Yu-Tzu; Catley Laurence P; Mitsiades Constantine S; Burger Renate; Podar Klaus; Shringpura Reshma; Hideshima Teru; Chauhan Dharminder; Hamaasaki Makoto; Ishitsuka Kenji; Richardson Paul; Treon Steven P; Munshi Nikhil C; Anderson Kenneth C (Reprint)
AUTHOR ADDRESS: Dana Farber Canc InstDept Med Oncol, Jerome Lipper Multiple Myeloma Ctr, M557, 44 Binney St, Boston, MA, 02115, USA**USA
AUTHOR E-MAIL ADDRESS: kennethanderson@dfci.harvard.edu
JOURNAL: Cancer Research 64 (8): p2846-2852 April 15, 2004 2004
MEDIUM: print
ISSN: 0008-5472 _(ISSN print)
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

17781212  BIOSIS NO.: 200400147873
Preclinical pharmacokinetics and pharmacodynamics of SGN-40, a humanized anti- CD40***antibody***
AUTHOR: Miller Dennis M (Reprint); Kelley Sean; Gelzleichter Tom; Grewal Iqbal; Darbonne W C
AUTHOR ADDRESS: Department of Clinical Affairs, Seattle Genetics, Inc., Bothell, WA, USA**USA
MEDIUM: print
CONFERENCE/MEETING: 45th Annual Meeting of the American Society of Hematology San Diego, CA, USA December 06-09, 2003; 20031206
SPONSOR: American Society of Hematology
ISSN: 0006-4971
DOCUMENT TYPE: Meeting; Meeting Abstract; Meeting Poster
RECORD TYPE: Abstract
LANGUAGE: English

17781045  BIOSIS NO.: 200400147706
Preclinical antitumor activity of a humanized anti-CD40 monoclonal antibody***SGN-40.
AUTHOR: Law Che-Leung (Reprint); Lee Wyne P; Lin Zhonghua; Grewal Iqbal S; Wahl Alan (Reprint)
AUTHOR ADDRESS: Department of Biochemistry, Seattle Genetics, Inc., Bothell, WA, USA**USA
MEDIUM: print
CONFERENCE/MEETING: 45th Annual Meeting of the American Society of Hematology San Diego, CA, USA December 06-09, 2003; 20031206
SPONSOR: American Society of Hematology
ISSN: 0006-4971
DOCUMENT TYPE: Meeting; Meeting Poster; Meeting Abstract
RECORD TYPE: Abstract
LANGUAGE: English

18/3/22 (Item 22 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.
15640053  BIOSIS NO.: 2000000358366
Agnostic properties and in vivo antitumor activity of the anti-CD40 antibody SGN-14
AUTHOR: Francisco Joseph A; Donaldson Karen L; Chace Dana; Siegall Clay B; Wahl Alan F (Reprint)
AUTHOR ADDRESS: Department of Biochemistry, Seattle Genetics, Inc., 22215
26th Avenue SE, Bothell, WA, 98021, USA**USA
MEDIUM: print
ISSN: 0008-5472
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

18/3/23 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.
0081797759  EMBASE No: 2007231792
Preliminary phase I evaluation of 2 anti-CD40 monoclonal antibodies in patients with relapsed/refractory multiple myeloma
Cunningham S.; Muneer S.; Ranganathan A.; Shivakumar L.; Lonial S.; Mughal T.; Armitage J.O.
Clinical Lymphoma and Myeloma (Clin. Lymphoma Myeloma) (United States) March 1, 2007, 7/5 (342-344)
ISSN: 1557-9190
DOCUMENT TYPE: Journal; Conference Paper RECORD TYPE: Citation
LANGUAGE: English
NUMBER OF REFERENCES: 47

18/3/24 (Item 2 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.
0081622101  EMBASE No: 2007055505
DOI: 10.1038/sj.bjp.0706828)
CODEN: BJPCB ISSN: 0007-1188 eiISSN: 1476-5381
18/3/25 (Item 3 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0081167302 EMBASE No: 2006229528
5th Annual International Congress on Monoclonal Antibodies in Cancer,
August 2005, Quebec City, Canada
Reddy G.K.; Jain V.K.; Nadler E.
Clinical Lymphoma and Myeloma (Clin. Lymphoma Myeloma) (United States)
September 1, 2005, 6/2 (71-76)
ISSN: 1557-9190
DOCUMENT TYPE: Journal; Conference Paper RECORD TYPE: Citation
LANGUAGE: English
NUMBER OF REFERENCES: 46

18/3/26 (Item 4 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0081037102 EMBASE No: 2006097101
Erratum: Preclinical antilymphoma activity of a humanized anti-CD40
monoclonal antibody, SGN-40 (Cancer Research (September 15,
2005) 65 (8331-8338)
Cancer Research (Cancer Res.) (United States) February 15, 2006, 66/4
(2495)
CODEN: CNREA ISSN: 0008-5472
DOI: 10.1158/0008-5472.CAN-06-4-COR
DOCUMENT TYPE: Journal; Erratum RECORD TYPE: Citation
LANGUAGE: English
NUMBER OF REFERENCES: 1

18/3/27 (Item 5 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0080618342 EMBASE No: 2005262633
From Hodgkin disease to Hodgkin lymphoma: Biologic insights and
therapeutic potential
Re D.; Thomas R.K.; Behringer K.; Diehl V.
Burnham Institute, John Reed Laboratory, 10901 N Torrey Pines Rd., San
Diego, CA 92037, United States
AUTHOR EMAIL: dre@burnham.org
CORRESP. AUTHOR/AFFIL: Re D.; Burnham Institute, John Reed Laboratory,
10901 N Torrey Pines Rd., San Diego, CA 92037, United States
CORRESP. EMAIL: dre@burnham.org
Blood (Blood) (United States) June 15, 2005, 105/12 (4553-4560)
CODEN: BLOOA ISSN: 0006-4971
DOI: 10.1182/blood-2004-12-4750
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 100

18/3/28  (Item 6 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0080559922  EMBASE No: 2005204182
Targeting signalling pathways for the treatment of multiple myeloma
Podar K.; Hideshima T.; Chauhan D.; Anderson K.C.
Dana-Farber Cancer Institute, Department of Medical Oncology, Harvard
Medical School, 44 Binney Street, Boston, MA 02115, United States
AUTHOR EMAIL: klaus; podar@dfci.harvard.edu
CORRESP. AUTHOR/AFFIL: Podar K.: Dana-Farber Cancer Institute, Department
of Medical Oncology, Harvard Medical School, 44 Binney Street, Boston, MA
02115, United States
CORRESP. AUTHOR EMAIL: klaus; podar@dfci.harvard.edu

Expert Opinion on Therapeutic Targets (Expert Opin. Ther. Targets) (1
United Kingdom) April 1, 2005, 9/2 (359-381)
CODEN: BDOTTA ISSN: 1472-8222
DOI: 10.1517/14728222.9.2.359
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 236

18/3/29  (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2008 American Chemical Society. All rts. reserv.

146314742  CA: 146(16)314742u  JOURNAL
Preclinical pharmacokinetics, pharmacodynamics, and activity of a
humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates.
(Erratum to document cited in CA145:290755)
AUTHOR(S): Kelley, Sean K.; Gelzleichter, Thomas; Xie, Dong; Lee, Wyne P.
; Darbonne, Walter C.; Qureshi, Ferhan; Kessler, Kim; Ofialzoglu, Ezogelin;
Grewal, Iqbal S.
LOCATION: Product Portfolio Management, Genentech Inc., South San
Francisco, CA, USA
VOLUME: 150 NUMBER: 2 PAGES: 248 CODEN: BJPCBM ISSN: 0007-1188
LANGUAGE: English PUBLISHER: Nature Publishing Group

18/3/30  (Item 2 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2008 American Chemical Society. All rts. reserv.

144368130  CA: 144(20)368130v  JOURNAL
preclinical antilymphoma activity of a humanized anti-CD40 monoclonal
antibody, SGN-40. (Erratum to document cited in CA143:284369)
AUTHOR(S): Law, Che-Leung; Gordon, Kristine A.; Collier, John; Klussman,
Kerry; McEarchern, Julie A.; Cerveny, Charles G.; Mixan, Bruce J.; Lee,
Wyne P.; Lin, Zhonghau; Valdez, Patricia; Wahl, Alan F.; Grewal, Iqbal S.
LOCATION: Seattle Genetics, Inc., Bothell, WA, USA
JOURNAL: Cancer Res. (Cancer Research) DATE: 2006 VOLUME: 66 NUMBER: 4
PAGES: 2495 CODEN: CNREA8 ISSN: 0008-5472 LANGUAGE: English
PUBLISHER: American Association for Cancer Research
? t s18/7/19,22
Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: Clinical implications

AUTHOR: Tai Yu-Tzu; Catley Laurence P; Mitsiades Constantine S; Burger Rene; Podar Klaus; Shingaprane Reshma; Hideshima Teru; Chauhan Dharminder; Hamasaki Makoto; Ishitsuka Kenji; Richardson Paul; Treon Steven P; Munshi Nikhil C; Anderson Kenneth C (Reprint)

AUTHOR ADDRESS: Dana Farber Canc InstDept Med Oncol, Jerome Lipper Multiple Myeloma Ctr, M557,44 Binney St, Boston, MA, 02115, USA**USA

AUTHOR E-MAIL ADDRESS: kennethanderson@dfci.harvard.edu

JOURNAL: Cancer Research 64 (8): p2846-2852 April 15, 2004 2004

MEDIUM: print

ISSN: 0008-5472 _(ISSN print)

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: CD40 is expressed on B-cell malignancies, including human multiple myeloma (MM) and a variety of carcinomas. We examined the potential therapeutic utility of SGN-40, the humanized anti-CD40 monoclonal antibody, for treating human MM using MM cell lines and patient MM cells (CD138++, ***CD40*** +). ***SGN*** -40 (0.01-100 mug/ml) induces modest cytotoxicity in MM cell lines and patient MM cells. In the presence of de novo protein synthesis inhibitor cycloheximide, SGN-40 significantly induced apoptosis in Dexamethasone (Dex)-sensitive MM.1S and Dex-resistant MM.1R cells and in patient MM cells. ***SGN*** -40-mediated cytotoxicity is associated with up-regulation of cytotoxic ligands of the tumor necrosis factor family (Fas/Fasl, tumor necrosis factor-related apoptosis-inducing ligand, and tumor necrosis factor a). ***SGN*** -40 treatment also induces a down-regulation of ***CD40*** dependent on an endocytic pathway. Consequently, pretreatment of MM cells with SGN-40 blocked sCD40L-mediated phosphatidylinositol 3'-kinase/AKT and nuclear factor kappaB activation. Importantly, pretreatment of MM.1S and MM.1R cells with SGN-40 inhibited proliferation triggered by interleukin 6 (IL-6) but not by insulin-like growth factor-I. In addition, ***SGN*** -40 pretreatment of MM.1S cells blocked the ability of IL-6 to protect against Dex-induced inhibition of DNA synthesis. This was associated with a 2-4-fold reduction of IL-6 receptor at protein and mRNA levels in ***SGN*** -40-treated MM.1S cells and patient MM cells. Taken together, these results provide the preclinical rationale for the evaluation of ***SGN*** -40 as a potential new therapy to improve patient outcome in MM.

Agonistic properties and in vivo antitumor activity of the anti-CD40 antibody SGN-14

AUTHOR: Francisco Joseph A; Donaldson Karen L; Chace Dana; Siegall Clay B; Wahl Alan F (Reprint)

AUTHOR ADDRESS: Department of Biochemistry, Seattle Genetics, Inc., 22215 26th Avenue SE, Bothell, WA, 98021, USA**USA

ABSTRACT: Ligation of CD40 is essential for primary B-cell activation and expansion and yet has suppressive or apoptotic effects on some CD40-expressing neoplasia. SGN-14 is a monoclonal antibody that binds to the human CD40 receptor. Here we report that SGN-14, in the presence of interleukin 4, provided a modest level of stimulation of peripheral blood B cells, as measured by proliferation. Stimulation was greatly enhanced in the presence of nonproliferating CD40 ligand-expressing cells. The enhanced agonistic activity could be attributed to a dose-dependent increase in CD40L binding to CD40 in the presence of SGN-14. In contrast to its proliferative effect on primary B cells, SGN-14 inhibited the growth of B-cell-derived tumor lines in vitro, and this growth inhibition was enhanced in the presence of CD40L-expressing cells. In vivo, SGN-14 showed significant antitumor activity in treating human B-cell lymphoma and multiple myeloma xenografted severe combined immunodeficient mice. Antitumor activity was not diminished by blunting murine natural killer activity, suggesting that CD40 ligation contributes to the antitumor efficacy of SGN-14. On the basis of these activities, SGN-14 is being pursued for therapeutic use in treating patients with CD40-expressing hematological malignancies.

<table>
<thead>
<tr>
<th>Set</th>
<th>Items</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>S1</td>
<td>15</td>
<td>(CD40) (1N) (AGONIST?) AND (CD20 OR RITUXAN OR RITUXIMAB)</td>
</tr>
<tr>
<td>S2</td>
<td>9</td>
<td>RD S1 (unique items)</td>
</tr>
<tr>
<td>S3</td>
<td>434</td>
<td>(CD40) (1N) (ANTIBOD? OR IMMUNOGLOBULIN?) AND (CD20 OR RITUXAN OR RITUXIMAB)</td>
</tr>
<tr>
<td>S4</td>
<td>280</td>
<td>S3 AND (CANCER? OR TUMOR? OR NEOPLAS? OR TUMOUR? OR LEUKEMIA? OR LYMPHOMA?)</td>
</tr>
<tr>
<td>S5</td>
<td>241</td>
<td>RD S4 (unique items)</td>
</tr>
<tr>
<td>S6</td>
<td>24</td>
<td>S5 AND (CD40) (2N) (AGONIST? OR STIMULAT? OR INCREAS?)</td>
</tr>
<tr>
<td>S7</td>
<td>24</td>
<td>RD S6 (unique items)</td>
</tr>
<tr>
<td>S8</td>
<td>0</td>
<td>S (CD40?) (2N) (AGONIST? OR STIMULAT? OR INCREAS?) AND (CD20 OR RITUXAN OR RITUXIMAB)</td>
</tr>
<tr>
<td>S9</td>
<td>193</td>
<td>(CD40?) (2N) (AGONIST? OR STIMULAT? OR INCREAS?) AND (CD20 OR RITUXAN OR RITUXIMAB)</td>
</tr>
<tr>
<td>S10</td>
<td>105</td>
<td>RD S9 (unique items)</td>
</tr>
<tr>
<td>S12</td>
<td>57</td>
<td>RD S11 (unique items)</td>
</tr>
<tr>
<td>S13</td>
<td>0</td>
<td>SS2C6 AND CD40</td>
</tr>
<tr>
<td>S14</td>
<td>17</td>
<td>S2C6 AND CD40</td>
</tr>
<tr>
<td>S15</td>
<td>9</td>
<td>RD S14 (unique items)</td>
</tr>
<tr>
<td>S16</td>
<td>67</td>
<td>SGN? AND CD40</td>
</tr>
<tr>
<td>S17</td>
<td>45</td>
<td>RD S16 (unique items)</td>
</tr>
<tr>
<td>S18</td>
<td>30</td>
<td>S17 AND (ANTIBOD? OR IMMUNOGLOBULIN) (2N) (SGN?)</td>
</tr>
</tbody>
</table>